,entity 1,entity 1 label,entity 2,entity 2 label,type
0,psilocybin,DRUG,psychological distress,OUTCOME,POSITIVELY IMPACTS
1,psilocybin,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
2,psilocybin,DRUG,suicidality,OUTCOME,POSITIVELY IMPACTS
3,mystical-type experience,SUBJECTIVE,anxiety,HEALTH,POSITIVELY IMPACTS
4,mystical-type experience,SUBJECTIVE,suicidality,OUTCOME,POSITIVELY IMPACTS
11,psilocybin,DRUG,depression,HEALTH,POSITIVELY IMPACTS
17,psilocybin,DRUG,psilocin,DRUG,POSITIVELY IMPACTS
20,hallucinogens,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
25,hallucinogens,DRUG,tolerated the treatment sessions well,OUTCOME,POSITIVELY IMPACTS
26,hallucinogens,DRUG,modest effects,OUTCOME,POSITIVELY IMPACTS
27,hallucinogens,DRUG,terminal cancer,HEALTH,POSITIVELY IMPACTS
28,hallucinogens,DRUG,"therapeutic outcome.10,12",OUTCOME,POSITIVELY IMPACTS
29,hallucinogens,DRUG,examining how Common illness had impacted Common lives,OUTCOME,POSITIVELY IMPACTS
30,hallucinogens,DRUG,relationships with family and close friends,OUTCOME,POSITIVELY IMPACTS
31,hallucinogens,DRUG,sense of ontological security,OUTCOME,POSITIVELY IMPACTS
32,hallucinogens,DRUG,powerful empathic cathexis to close friends and family members,OUTCOME,POSITIVELY IMPACTS
33,hallucinogens,DRUG,how subjects wished to address subjects limited life expectancy,OUTCOME,POSITIVELY IMPACTS
34,hallucinogens,DRUG,pronounced therapeutic effects,OUTCOME,POSITIVELY IMPACTS
35,psilocybin,DRUG,therapeutic benefit,OUTCOME,POSITIVELY IMPACTS
37,psilocybin,DRUG,stress,HEALTH,POSITIVELY IMPACTS
39,psilocybin,DRUG,mood,OUTCOME,POSITIVELY IMPACTS
40,positive outcome,OUTCOME,mood,OUTCOME,POSITIVELY IMPACTS
44,psilocybin,DRUG,mood-elevating effects,OUTCOME,POSITIVELY IMPACTS
48,psilocybin,DRUG,strong therapeutic bonds,OUTCOME,POSITIVELY IMPACTS
49,psilocybin,DRUG,ameliorating underlying psychological demoralization,OUTCOME,POSITIVELY IMPACTS
50,psilocybin,DRUG,existential anxiety,HEALTH,POSITIVELY IMPACTS
51,psilocybin,DRUG,despair,HEALTH,POSITIVELY IMPACTS
54,safety and promise,OUTCOME,existential anxiety,HEALTH,POSITIVELY IMPACTS
55,safety and promise,OUTCOME,despair,HEALTH,POSITIVELY IMPACTS
56,hallucinogenic compounds,DRUG,existential anxiety,HEALTH,POSITIVELY IMPACTS
57,hallucinogenic compounds,DRUG,despair,HEALTH,POSITIVELY IMPACTS
60,LSD,DRUG,therapeutic improvement,OUTCOME,POSITIVELY IMPACTS
62,LSD,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
63,LSD,DRUG,depression,HEALTH,POSITIVELY IMPACTS
66,psilocybin,DRUG,favourable toxicity profile,OUTCOME,POSITIVELY IMPACTS
67,psilocybin,DRUG,not associated with compulsive drug-seeking behaviours,OUTCOME,POSITIVELY IMPACTS
69,ketamine,DRUG,smokers,HEALTH,POSITIVELY IMPACTS
70,ketamine,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
71,ketamine,DRUG,depression,HEALTH,POSITIVELY IMPACTS
72,psilocybin,DRUG,smokers,HEALTH,POSITIVELY IMPACTS
76,psilocybin,DRUG,clinical improvements,OUTCOME,POSITIVELY IMPACTS
79,suggestibility,OUTCOME,antidepressant,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
84,psychedelics,DRUG,novel pharmacological action,OUTCOME,POSITIVELY IMPACTS
85,psilocybin,DRUG,novel pharmacological action,OUTCOME,POSITIVELY IMPACTS
86,Psilocybin,DRUG,antidepressant,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
87,Psilocybin,DRUG,novel pharmacological action,OUTCOME,POSITIVELY IMPACTS
92,psychedelics,DRUG,subjective and behavioral effects,OUTCOME,POSITIVELY IMPACTS
127,PCC,NEURAL,self,SUBJECTIVE,POSITIVELY IMPACTS
128,DMN,NEURAL,ego,SUBJECTIVE,POSITIVELY IMPACTS
130,connector hubs,OUTCOME,self,SUBJECTIVE,POSITIVELY IMPACTS
131,connector hubs,OUTCOME,ego,SUBJECTIVE,POSITIVELY IMPACTS
132,connector hubs,OUTCOME,efficient information transfer,OUTCOME,POSITIVELY IMPACTS
133,connector hubs,OUTCOME,allowing communication between different regions,OUTCOME,POSITIVELY IMPACTS
134,psilocybin,DRUG,efficient information transfer,OUTCOME,POSITIVELY IMPACTS
135,psilocybin,DRUG,allowing communication between different regions,OUTCOME,POSITIVELY IMPACTS
146,psilocybin,DRUG,“overstable” state,SUBJECTIVE,POSITIVELY IMPACTS
147,psilocybin,DRUG,subjective well-being,OUTCOME,POSITIVELY IMPACTS
148,psilocybin,DRUG,trait openness,OUTCOME,POSITIVELY IMPACTS
150,psilocybin,DRUG,terminal cancer patients,HEALTH,POSITIVELY IMPACTS
151,psilocybin,DRUG,decreased CBF in the hypothalamus,OUTCOME,POSITIVELY IMPACTS
156,psychedelics,DRUG,terminal cancer patients,HEALTH,POSITIVELY IMPACTS
157,psychedelics,DRUG,decreased CBF in the hypothalamus,OUTCOME,POSITIVELY IMPACTS
158,psychedelics,DRUG,cluster headaches,HEALTH,POSITIVELY IMPACTS
159,Increased hypothalamic CBF,OUTCOME,cluster headaches,HEALTH,POSITIVELY IMPACTS
160,psychedelic state,SUBJECTIVE,cluster headaches,HEALTH,POSITIVELY IMPACTS
163,psilocybin,DRUG,"rapid, robust, and sustained clinical benefits",OUTCOME,POSITIVELY IMPACTS
166,psilocybin,DRUG,clinical benefits,OUTCOME,POSITIVELY IMPACTS
167,psilocybin,DRUG,cancer-related anxiety,HEALTH,POSITIVELY IMPACTS
181,psilocybin,DRUG,anti-depressant effects,OUTCOME,POSITIVELY IMPACTS
185,psilocybin,DRUG,clinical outcomes,OUTCOME,POSITIVELY IMPACTS
189,psilocybin,DRUG,rapid anti-depressant and anxiolytic clinical benefits,OUTCOME,POSITIVELY IMPACTS
197,psilocybin,DRUG,anti-depressant response rates,OUTCOME,POSITIVELY IMPACTS
201,Psilocybin,DRUG,rapid anti-depressant and anxiolytic clinical benefits,OUTCOME,POSITIVELY IMPACTS
202,Psilocybin,DRUG,clinical outcomes,OUTCOME,POSITIVELY IMPACTS
203,Psilocybin,DRUG,anti-depressant response rates,OUTCOME,POSITIVELY IMPACTS
204,Psilocybin,DRUG,cancer-related depression,HEALTH,POSITIVELY IMPACTS
205,Psilocybin,DRUG,anti-depressants,DRUG,POSITIVELY IMPACTS
206,Psilocybin,DRUG,cancer-related demoralization,OUTCOME,POSITIVELY IMPACTS
207,psilocybin,DRUG,decreased quality of life,OUTCOME,POSITIVELY IMPACTS
209,psilocybin,DRUG,improved attitudes and adaptations to death,OUTCOME,POSITIVELY IMPACTS
210,psilocybin,DRUG,highly meaningful and spiritual,OUTCOME,POSITIVELY IMPACTS
211,Psilocybin,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
212,Psilocybin,DRUG,improved attitudes and adaptations to death,OUTCOME,POSITIVELY IMPACTS
213,Psilocybin,DRUG,highly meaningful and spiritual,OUTCOME,POSITIVELY IMPACTS
214,psilocybin,DRUG,increased rates of mental illness,OUTCOME,POSITIVELY IMPACTS
216,serotoninergic psychedelic,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
217,ayahuasca,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
218,ayahuasca,DRUG,rapid and sustained anti-depressant effects,OUTCOME,POSITIVELY IMPACTS
219,ayahuasca,DRUG,depression,HEALTH,POSITIVELY IMPACTS
220,ayahuasca,DRUG,suicidality,HEALTH,POSITIVELY IMPACTS
221,selective serotonin reuptake inhibitors,ANTIDEPRESSANT_DRUG,depression,HEALTH,POSITIVELY IMPACTS
222,selective serotonin reuptake inhibitors,ANTIDEPRESSANT_DRUG,suicidality,HEALTH,POSITIVELY IMPACTS
223,selective serotonin reuptake inhibitors,ANTIDEPRESSANT_DRUG,depressed patients,HEALTH,POSITIVELY IMPACTS
224,selective serotonin reuptake inhibitors,ANTIDEPRESSANT_DRUG,tricyclic anti-depressants),ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
225,ketamine,DRUG,anti-depressant mechanisms of action,OUTCOME,POSITIVELY IMPACTS
226,ketamine,DRUG,anti-depressant treatment,OUTCOME,POSITIVELY IMPACTS
228,ketamine,DRUG,decreased connectivity,OUTCOME,POSITIVELY IMPACTS
232,mystical-type experiences,SUBJECTIVE,anxiety,HEALTH,POSITIVELY IMPACTS
233,mystical-type experiences,SUBJECTIVE,depression,HEALTH,POSITIVELY IMPACTS
234,subjective mystical experience,SUBJECTIVE,anxiety,HEALTH,POSITIVELY IMPACTS
235,subjective mystical experience,SUBJECTIVE,depression,HEALTH,POSITIVELY IMPACTS
236,mystical experience,SUBJECTIVE,cancer patients,HEALTH,POSITIVELY IMPACTS
237,mystical experience,SUBJECTIVE,clinical benefit,OUTCOME,POSITIVELY IMPACTS
238,mystical experience,SUBJECTIVE,anxiety,HEALTH,POSITIVELY IMPACTS
239,mystical experience,SUBJECTIVE,depression,HEALTH,POSITIVELY IMPACTS
240,mystical experience,SUBJECTIVE,terminal cancer,HEALTH,POSITIVELY IMPACTS
241,mystical experience,SUBJECTIVE,improved clinical outcomes,OUTCOME,POSITIVELY IMPACTS
242,psilocybin,DRUG,clinical benefit,OUTCOME,POSITIVELY IMPACTS
245,psilocybin,DRUG,terminal cancer,HEALTH,POSITIVELY IMPACTS
246,psilocybin,DRUG,tobacco addiction,HEALTH,POSITIVELY IMPACTS
247,psilocybin,DRUG,alcoholism,HEALTH,POSITIVELY IMPACTS
248,psilocybin,DRUG,improved clinical outcomes,OUTCOME,POSITIVELY IMPACTS
249,psilocybin,DRUG,psycho-spiritual mechanism of action,OUTCOME,POSITIVELY IMPACTS
250,psilocybin,DRUG,mystical state of consciousness,SUBJECTIVE,POSITIVELY IMPACTS
255,psychedelic,DRUG,self,SUBJECTIVE,POSITIVELY IMPACTS
256,Psychedelics,DRUG,self,SUBJECTIVE,POSITIVELY IMPACTS
257,personal conflicts,OUTCOME,ego,SUBJECTIVE,POSITIVELY IMPACTS
258,personal conflicts,OUTCOME,self,SUBJECTIVE,POSITIVELY IMPACTS
259,profound existential or “peak” experiences,OUTCOME,self,SUBJECTIVE,POSITIVELY IMPACTS
260,lasting positive impact on behavior and outlook,OUTCOME,self,SUBJECTIVE,POSITIVELY IMPACTS
261,nature,SUBJECTIVE,ego,SUBJECTIVE,POSITIVELY IMPACTS
262,nature,SUBJECTIVE,self,SUBJECTIVE,POSITIVELY IMPACTS
263,psychedelics,DRUG,self,SUBJECTIVE,POSITIVELY IMPACTS
264,disintegration,OUTCOME,self,SUBJECTIVE,POSITIVELY IMPACTS
266,psychoanalysis,NEURAL,considerable explanatory value,OUTCOME,POSITIVELY IMPACTS
267,AYA,DRUG,antidepressive effects,OUTCOME,POSITIVELY IMPACTS
268,AYA,DRUG,depression,HEALTH,POSITIVELY IMPACTS
269,AYA,DRUG,therapeutic action,OUTCOME,POSITIVELY IMPACTS
272,AYA,DRUG,faster reductions in depressive symptoms,OUTCOME,POSITIVELY IMPACTS
274,ketamine,DRUG,antidepressive effects,OUTCOME,POSITIVELY IMPACTS
277,ketamine,DRUG,brain-derived neurotrophic factor,NEURAL,POSITIVELY IMPACTS
278,THH,DRUG,brain-derived neurotrophic factor,NEURAL,POSITIVELY IMPACTS
279,THH,DRUG,systems - MAO,NEURAL,POSITIVELY IMPACTS
280,THH,DRUG,elevated levels of brain serotonin,OUTCOME,POSITIVELY IMPACTS
281,THH,DRUG,antidepressant effects,OUTCOME,POSITIVELY IMPACTS
282,AYA,DRUG,depressed patients,HEALTH,POSITIVELY IMPACTS
285,AYA,DRUG,experience as pleasant despite the occurrence of vomiting,OUTCOME,POSITIVELY IMPACTS
290,purgative effects,OUTCOME,cleansing,OUTCOME,POSITIVELY IMPACTS
294,AYA,DRUG,antidepressive potentials,OUTCOME,POSITIVELY IMPACTS
295,AYA,DRUG,faster therapeutic actions,OUTCOME,POSITIVELY IMPACTS
296,AYA,DRUG,making antidepressive treatment more effective,OUTCOME,POSITIVELY IMPACTS
297,psychedelics,DRUG,plasticity related processes,OUTCOME,POSITIVELY IMPACTS
298,compounds,DRUG,MDMA,DRUG,POSITIVELY IMPACTS
299,compounds,DRUG,medicinal value,OUTCOME,POSITIVELY IMPACTS
300,psychedelic,DRUG,enhancing plasticity and adaptability,OUTCOME,POSITIVELY IMPACTS
301,psychedelics,DRUG,self-consciousness,SUBJECTIVE,POSITIVELY IMPACTS
303,psychedelics,DRUG,sense of self,SUBJECTIVE,POSITIVELY IMPACTS
304,psilocybe,DRUG,sense of self,SUBJECTIVE,POSITIVELY IMPACTS
305,brain serotonin,NEURAL,resilience,OUTCOME,POSITIVELY IMPACTS
306,serotonin,NEURAL,engagement of 5-HT receptor subtypes,NEURAL,POSITIVELY IMPACTS
307,serotonin,NEURAL,mood,OUTCOME,POSITIVELY IMPACTS
308,serotonergic psychedelics,DRUG,changes in mood,OUTCOME,POSITIVELY IMPACTS
309,serotonergic psychedelics,DRUG,brain function,NEURAL,POSITIVELY IMPACTS
310,drugs,DRUG,changes in mood,OUTCOME,POSITIVELY IMPACTS
311,drugs,DRUG,brain function,NEURAL,POSITIVELY IMPACTS
312,psychedelics,DRUG,changes in mood,OUTCOME,POSITIVELY IMPACTS
313,psychedelics,DRUG,brain function,NEURAL,POSITIVELY IMPACTS
315,psychedelics,DRUG,transiently increasing the size of dendritic spines on cortical neurons,OUTCOME,POSITIVELY IMPACTS
316,DOI,DRUG,cell line of neuronal lineage,NEURAL,POSITIVELY IMPACTS
317,psychedelics,DRUG,cell line of neuronal lineage,NEURAL,POSITIVELY IMPACTS
318,ketamine,DRUG,tryptamine,DRUG,POSITIVELY IMPACTS
319,ketamine,DRUG,GLYX-13,NEURAL,POSITIVELY IMPACTS
320,LSD,DRUG,invertebrate,DRUG,POSITIVELY IMPACTS
321,psychedelics,DRUG,invertebrate,DRUG,POSITIVELY IMPACTS
322,psychedelics,DRUG,brain,NEURAL,POSITIVELY IMPACTS
323,psychedelics,DRUG,promote changes in the density of dendritic spines,OUTCOME,POSITIVELY IMPACTS
324,psychedelics,DRUG,spontaneous EPSCs,NEURAL,POSITIVELY IMPACTS
326,compounds,DRUG,spontaneous EPSCs,NEURAL,POSITIVELY IMPACTS
328,psychedelics,DRUG,profound perceptual disturbances,OUTCOME,POSITIVELY IMPACTS
329,compounds,DRUG,profound perceptual disturbances,OUTCOME,POSITIVELY IMPACTS
330,compounds,DRUG,promoting plasticity,OUTCOME,POSITIVELY IMPACTS
331,compounds,DRUG,neuropsychiatric diseases,HEALTH,POSITIVELY IMPACTS
332,TrkB,NEURAL,promoting plasticity,OUTCOME,POSITIVELY IMPACTS
333,TrkB,NEURAL,neuropsychiatric diseases,HEALTH,POSITIVELY IMPACTS
335,psychedelics,DRUG,non-hallucinogenic analogs,DRUG,POSITIVELY IMPACTS
336,psychedelics,DRUG,promoting plasticity,OUTCOME,POSITIVELY IMPACTS
337,psychedelics,DRUG,neuropsychiatric diseases,HEALTH,POSITIVELY IMPACTS
338,psychedelics,DRUG,therapeutic effects,OUTCOME,POSITIVELY IMPACTS
345,non-hallucinogenic analogs,DRUG,promoting plasticity,OUTCOME,POSITIVELY IMPACTS
346,non-hallucinogenic analogs,DRUG,neuropsychiatric diseases,HEALTH,POSITIVELY IMPACTS
351,psychedelics,DRUG,promoting the growth of both neurites and dendritic spines,OUTCOME,POSITIVELY IMPACTS
357,ketamine,DRUG,promoting the growth of both neurites and dendritic spines,OUTCOME,POSITIVELY IMPACTS
360,efficacy,OUTCOME,depression,HEALTH,POSITIVELY IMPACTS
361,efficacy,OUTCOME,anxiety,HEALTH,POSITIVELY IMPACTS
362,psychedelic,DRUG,cost-effectiveness,OUTCOME,POSITIVELY IMPACTS
363,psilocybin,DRUG,therapeutic actions,OUTCOME,POSITIVELY IMPACTS
364,SSRIs,ANTIDEPRESSANT_DRUG,therapeutic actions,OUTCOME,POSITIVELY IMPACTS
365,ayahuasca,DRUG,rapid and sustained antidepressive effects,OUTCOME,POSITIVELY IMPACTS
366,ayahuasca,DRUG,subgenual area,NEURAL,POSITIVELY IMPACTS
367,ayahuasca,DRUG,brain,NEURAL,POSITIVELY IMPACTS
368,ayahuasca,DRUG,drug effects,OUTCOME,POSITIVELY IMPACTS
369,ayahuasca,DRUG,depressed mood,HEALTH,POSITIVELY IMPACTS
371,ayahuasca,DRUG,feelings of guilt,OUTCOME,POSITIVELY IMPACTS
376,ayahuasca,DRUG,emotional withdrawal,OUTCOME,POSITIVELY IMPACTS
377,ayahuasca,DRUG,bipolar disorder,HEALTH,POSITIVELY IMPACTS
379,ayahuasca,DRUG,antidepressive effects.13–17,OUTCOME,POSITIVELY IMPACTS
383,LSD,DRUG,antidepressive effects.13–17,OUTCOME,POSITIVELY IMPACTS
384,LSD,DRUG,ayahuasca25,DRUG,POSITIVELY IMPACTS
385,ayahuasca,DRUG,psychoactive effects,OUTCOME,POSITIVELY IMPACTS
386,ketamine,DRUG,antidepressant drug,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
389,ketamine,DRUG,immediate effects on many behavioral tests,OUTCOME,POSITIVELY IMPACTS
397,ketamine,DRUG,rapid and sustained molecular alterations,OUTCOME,POSITIVELY IMPACTS
398,BCl,DRUG,rapid and sustained molecular alterations,OUTCOME,POSITIVELY IMPACTS
399,ketamine,DRUG,neuronal survival,NEURAL,POSITIVELY IMPACTS
402,TRD,HEALTH,neuronal survival,NEURAL,POSITIVELY IMPACTS
403,TRD,HEALTH,mTOR,NEURAL,POSITIVELY IMPACTS
404,TRD,HEALTH,synaptic plasticity,NEURAL,POSITIVELY IMPACTS
406,psilocybin,DRUG,hallucinogen,DRUG,POSITIVELY IMPACTS
408,psilocybin,DRUG,less positive clinical outcomes,OUTCOME,POSITIVELY IMPACTS
409,psilocybin,DRUG,long-term positive clinical outcomes,OUTCOME,POSITIVELY IMPACTS
410,catharsis,DRUG,emotional insight,OUTCOME,POSITIVELY IMPACTS
411,catharsis,DRUG,closure,OUTCOME,POSITIVELY IMPACTS
417,mystical-type experience,SUBJECTIVE,brain systems,NEURAL,POSITIVELY IMPACTS
418,psychedelic,DRUG,post-acute brain effects,OUTCOME,POSITIVELY IMPACTS
419,psychedelic,DRUG,"modular disintegration14,15,28",OUTCOME,POSITIVELY IMPACTS
420,psychedelic,DRUG,depression,HEALTH,POSITIVELY IMPACTS
421,psychedelic,DRUG,decreased CBF,OUTCOME,POSITIVELY IMPACTS
422,LSD14,DRUG,decreased CBF,OUTCOME,POSITIVELY IMPACTS
423,LSD14,DRUG,amygdala,NEURAL,POSITIVELY IMPACTS
424,LSD14,DRUG,depressed mood,HEALTH,POSITIVELY IMPACTS
425,sgACC,NEURAL,depressed mood,HEALTH,POSITIVELY IMPACTS
426,ECT,ANTIDEPRESSANT_DRUG,depression,HEALTH,POSITIVELY IMPACTS
427,amygdala45,NEURAL,amygdala,NEURAL,POSITIVELY IMPACTS
428,increased CBF,OUTCOME,metabolism in,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
429,increased CBF,OUTCOME,"mood disorders25,43,44",HEALTH,POSITIVELY IMPACTS
430,increased CBF,OUTCOME,amygdala,NEURAL,POSITIVELY IMPACTS
431,increased CBF,OUTCOME,increase in CBF,OUTCOME,POSITIVELY IMPACTS
432,increased CBF,OUTCOME,decreased CBF,OUTCOME,POSITIVELY IMPACTS
433,increased CBF,OUTCOME,increases in brain absolute CBF30,OUTCOME,POSITIVELY IMPACTS
434,increased CBF,OUTCOME,depression,HEALTH,POSITIVELY IMPACTS
435,LSD15,DRUG,amygdala,NEURAL,POSITIVELY IMPACTS
436,increased glucose metabolism,OUTCOME,amygdala,NEURAL,POSITIVELY IMPACTS
437,citalopram,ANTIDEPRESSANT_DRUG,amygdala,NEURAL,POSITIVELY IMPACTS
438,psilocybin,DRUG,neuropsychiatric disorders,HEALTH,POSITIVELY IMPACTS
439,psilocybin,DRUG,biases emotional processing,OUTCOME,POSITIVELY IMPACTS
440,ketanserin,ANTIDEPRESSANT_DRUG,biases emotional processing,OUTCOME,POSITIVELY IMPACTS
441,ketanserin,ANTIDEPRESSANT_DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
442,ketanserin,ANTIDEPRESSANT_DRUG,mood effects,OUTCOME,POSITIVELY IMPACTS
445,psilocybin,DRUG,mood effects,OUTCOME,POSITIVELY IMPACTS
446,Psilocybin,DRUG,increase in the positive affect but not negative affect,OUTCOME,POSITIVELY IMPACTS
448,Psilocybin,DRUG,mood effects,OUTCOME,POSITIVELY IMPACTS
449,Psilocybin,DRUG,tryptophan depletion,NEURAL,POSITIVELY IMPACTS
452,ketanserin,DRUG,tryptophan depletion,NEURAL,POSITIVELY IMPACTS
453,ketanserin,DRUG,mood,OUTCOME,POSITIVELY IMPACTS
454,ketanserin,DRUG,mood-enhancing effects,OUTCOME,POSITIVELY IMPACTS
458,ketanserin,DRUG,5-HT2A antagonist,NEURAL,POSITIVELY IMPACTS
461,ketanserin,DRUG,5-HT2A,NEURAL,POSITIVELY IMPACTS
462,ketanserin,DRUG,5-HT2C receptors,NEURAL,POSITIVELY IMPACTS
463,ketanserin,DRUG,Mental Health,HEALTH,POSITIVELY IMPACTS
464,ketanserin,DRUG,serotonin 2B/5-HT2C agonist,NEURAL,POSITIVELY IMPACTS
472,psilocybin,DRUG,increase in reaction times to negative and neutral,OUTCOME,POSITIVELY IMPACTS
473,psilocybin,DRUG,decreased reaction times,OUTCOME,POSITIVELY IMPACTS
474,psilocybin,DRUG,event-related potentials,OUTCOME,POSITIVELY IMPACTS
475,psilocybin,DRUG,word valence,SUBJECTIVE,POSITIVELY IMPACTS
476,psilocybin,DRUG,attention,SUBJECTIVE,POSITIVELY IMPACTS
477,psilocybin,DRUG,enhanced P3 component,OUTCOME,POSITIVELY IMPACTS
480,ketanserin,DRUG,event-related potentials,OUTCOME,POSITIVELY IMPACTS
481,ketanserin,DRUG,word valence,SUBJECTIVE,POSITIVELY IMPACTS
482,ketanserin,DRUG,attention,SUBJECTIVE,POSITIVELY IMPACTS
483,ketanserin,DRUG,enhanced P3 component,OUTCOME,POSITIVELY IMPACTS
484,ketanserin,DRUG,decreased the P300 component,OUTCOME,POSITIVELY IMPACTS
488,psilocybin,DRUG,N2,NEURAL,POSITIVELY IMPACTS
490,psilocybin,DRUG,decreased the P300 component,OUTCOME,POSITIVELY IMPACTS
491,psilocybin,DRUG,valence-dependent P300 decrease,OUTCOME,POSITIVELY IMPACTS
492,psilocybin,DRUG,attentional performance,OUTCOME,POSITIVELY IMPACTS
493,psilocybin,DRUG,attenuate the allocation of attentional resources to neutral and negative stimuli,OUTCOME,POSITIVELY IMPACTS
504,psilocybin,DRUG,sustained adaptations,OUTCOME,POSITIVELY IMPACTS
505,psilocybin,DRUG,depressed subjects,HEALTH,POSITIVELY IMPACTS
506,psilocybin,DRUG,increased P300 component,OUTCOME,POSITIVELY IMPACTS
507,psilocybin,DRUG,shift dysfunctional emotional biases,OUTCOME,POSITIVELY IMPACTS
510,psilocybin,DRUG,emotional biases,OUTCOME,POSITIVELY IMPACTS
511,psilocybin,DRUG,negative emotional biases,OUTCOME,POSITIVELY IMPACTS
513,psilocybin,DRUG,negative mood states,SUBJECTIVE,POSITIVELY IMPACTS
514,psilocybin,DRUG,dysfunctional emotional biases,OUTCOME,POSITIVELY IMPACTS
515,psilocybin,DRUG,depressed patients,HEALTH,POSITIVELY IMPACTS
517,ketamine,DRUG,treatment-resistant depression,HEALTH,POSITIVELY IMPACTS
519,ayahuasca,DRUG,treatment-resistant depression,HEALTH,POSITIVELY IMPACTS
520,ayahuasca,DRUG,mood disorders,HEALTH,POSITIVELY IMPACTS
522,ayahuasca,DRUG,depressive symptoms,OUTCOME,POSITIVELY IMPACTS
523,ayahuasca,DRUG,enhanced mindfulness-related capacities,OUTCOME,POSITIVELY IMPACTS
528,ayahuasca,DRUG,Brain circuits,NEURAL,POSITIVELY IMPACTS
530,ayahuasca,DRUG,brain regions,NEURAL,POSITIVELY IMPACTS
531,ayahuasca,DRUG,left subgenual area,NEURAL,POSITIVELY IMPACTS
535,ayahuasca,DRUG,meditation practices,OUTCOME,POSITIVELY IMPACTS
542,psychedelic,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
543,psychedelic,DRUG,depressive symptoms,OUTCOME,POSITIVELY IMPACTS
544,psychedelic,DRUG,enhanced mindfulness-related capacities,OUTCOME,POSITIVELY IMPACTS
546,psychedelics,DRUG,treatment-resistant depression,HEALTH,POSITIVELY IMPACTS
547,psychedelics,DRUG,depression,HEALTH,POSITIVELY IMPACTS
548,psychedelics,DRUG,double blindness,OUTCOME,POSITIVELY IMPACTS
549,psychedelics,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
550,ayahuasca,DRUG,double blindness,OUTCOME,POSITIVELY IMPACTS
553,ayahuasca,DRUG,alcohol dependence,HEALTH,POSITIVELY IMPACTS
554,psychedelics,DRUG,alcohol dependence,HEALTH,POSITIVELY IMPACTS
556,LSD,DRUG,antiaddictive,OUTCOME,POSITIVELY IMPACTS
557,psilocybin,DRUG,antiaddictive,OUTCOME,POSITIVELY IMPACTS
559,ayahuasca,DRUG,antiaddictive,OUTCOME,POSITIVELY IMPACTS
560,psilocybin,DRUG,therapeutic potentials,OUTCOME,POSITIVELY IMPACTS
561,LSD,DRUG,therapeutic potentials,OUTCOME,POSITIVELY IMPACTS
562,DMT,DRUG,therapeutic potentials,OUTCOME,POSITIVELY IMPACTS
565,LSD,DRUG,depressed patients,HEALTH,POSITIVELY IMPACTS
566,serotonin 5-HT1A/2A/2C receptors,NEURAL,therapeutic potentials,OUTCOME,POSITIVELY IMPACTS
567,5-HT1A/2A/2C receptor,NEURAL,depression,HEALTH,POSITIVELY IMPACTS
571,psilocybin,DRUG,hippocampus,NEURAL,POSITIVELY IMPACTS
575,DMT,DRUG,"chemokine (Mcp-1, Cx3cl1) genes",NEURAL,POSITIVELY IMPACTS
576,DMT,DRUG,Th1/Th17 responses,NEURAL,POSITIVELY IMPACTS
577,THH,DRUG,Th1/Th17 responses,NEURAL,POSITIVELY IMPACTS
578,harmine,DRUG,depression,HEALTH,POSITIVELY IMPACTS
579,harmine,DRUG,antioxidant and neuroprotective effects,OUTCOME,POSITIVELY IMPACTS
580,psilocybin,DRUG,antiaddictive potentials,OUTCOME,POSITIVELY IMPACTS
582,compounds,DRUG,intensification of the self-reference process of rumination,OUTCOME,POSITIVELY IMPACTS
585,ayahuasca,DRUG,drug dependence,OUTCOME,POSITIVELY IMPACTS
587,psilocybin,DRUG,mood disorders,HEALTH,POSITIVELY IMPACTS
588,psilocybin,DRUG,drug dependence,OUTCOME,POSITIVELY IMPACTS
589,altered state of consciousness,SUBJECTIVE,anxiety,HEALTH,POSITIVELY IMPACTS
590,altered state of consciousness,SUBJECTIVE,mood disorders,HEALTH,POSITIVELY IMPACTS
591,altered state of consciousness,SUBJECTIVE,drug dependence,OUTCOME,POSITIVELY IMPACTS
592,classical hallucinogens,DRUG,mood disorders,HEALTH,POSITIVELY IMPACTS
593,psilocybin,DRUG,induces highly meaningful and spiritually significant experiences,OUTCOME,POSITIVELY IMPACTS
595,psilocybin,DRUG,smoking cessation,OUTCOME,POSITIVELY IMPACTS
599,LSD,DRUG,tobacco dependence,OUTCOME,POSITIVELY IMPACTS
600,LSD,DRUG,spiritual significance,OUTCOME,POSITIVELY IMPACTS
601,LSD,DRUG,impact on well-being,OUTCOME,POSITIVELY IMPACTS
602,LSD,DRUG,smoking cessation,OUTCOME,POSITIVELY IMPACTS
603,LSD,DRUG,"long-term beneficial changes in perspectives, attitudes, values, and quality of life",OUTCOME,POSITIVELY IMPACTS
604,hallucinogens,DRUG,antiaddictive,OUTCOME,POSITIVELY IMPACTS
605,hallucinogens,DRUG,lasting beneficial changes,OUTCOME,POSITIVELY IMPACTS
609,LSD,DRUG,dying cancer patients.2,HEALTH,POSITIVELY IMPACTS
610,LSD,DRUG,mood,OUTCOME,POSITIVELY IMPACTS
611,LSD,DRUG,reduced anxiety,OUTCOME,POSITIVELY IMPACTS
612,LSD,DRUG,fear of death,OUTCOME,POSITIVELY IMPACTS
613,LSD,DRUG,advanced-stage cancer,HEALTH,POSITIVELY IMPACTS
614,LSD,DRUG,advanced-stage cancer cancer,HEALTH,POSITIVELY IMPACTS
616,psilocybin,DRUG,reduced anxiety,OUTCOME,POSITIVELY IMPACTS
617,psilocybin,DRUG,fear of death,OUTCOME,POSITIVELY IMPACTS
618,Psilocybin,DRUG,mood,OUTCOME,POSITIVELY IMPACTS
619,Psilocybin,DRUG,reduced anxiety,OUTCOME,POSITIVELY IMPACTS
621,Psilocybe,DRUG,mood,OUTCOME,POSITIVELY IMPACTS
625,psilocybin,DRUG,cancer-related psychosocial distress,HEALTH,POSITIVELY IMPACTS
627,psilocybin,DRUG,Anxiety,HEALTH,POSITIVELY IMPACTS
628,mystical experience,SUBJECTIVE,mood,OUTCOME,POSITIVELY IMPACTS
631,psilocybin,DRUG,cancer diagnosis,HEALTH,POSITIVELY IMPACTS
632,psilocybin,DRUG,improved attitudes toward disease progression and death,OUTCOME,POSITIVELY IMPACTS
633,psilocybin,DRUG,improved quality of life,OUTCOME,POSITIVELY IMPACTS
634,LSD,DRUG,cancer,HEALTH,POSITIVELY IMPACTS
635,LSD,DRUG,anxiolytic and antidepressant effects,OUTCOME,POSITIVELY IMPACTS
636,LSD,DRUG,improved attitudes toward disease progression and death,OUTCOME,POSITIVELY IMPACTS
637,LSD,DRUG,improved quality of life,OUTCOME,POSITIVELY IMPACTS
643,subjective experiences,SUBJECTIVE,anxiety,HEALTH,POSITIVELY IMPACTS
646,LSD,DRUG,marked improvement in depressive symptoms,OUTCOME,POSITIVELY IMPACTS
649,psilocybin,DRUG,amygdala,NEURAL,POSITIVELY IMPACTS
653,psilocybin,DRUG,normalize limbic hyperactivity,OUTCOME,POSITIVELY IMPACTS
654,psilocybin,DRUG,depressed mood state,HEALTH,POSITIVELY IMPACTS
670,psilocybin,DRUG,reduction of amygdala reactivity,OUTCOME,POSITIVELY IMPACTS
672,psilocybin,DRUG,emotion processing,OUTCOME,POSITIVELY IMPACTS
675,SSRIs,ANTIDEPRESSANT_DRUG,amygdala,NEURAL,POSITIVELY IMPACTS
676,serotonin transporters,NEURAL,amygdala,NEURAL,POSITIVELY IMPACTS
677,psilocybin,DRUG,decreased activation in the visual cortex,OUTCOME,POSITIVELY IMPACTS
678,psilocybin,DRUG,decrease of activation in the visual cortex,OUTCOME,POSITIVELY IMPACTS
680,psilocybin,DRUG,processing of threat-related signals,OUTCOME,POSITIVELY IMPACTS
681,psilocybin,DRUG,attenuation of amygdala activation,OUTCOME,POSITIVELY IMPACTS
685,psilocybin,DRUG,emotion,SUBJECTIVE,POSITIVELY IMPACTS
688,ketanserin,DRUG,amygdala,NEURAL,POSITIVELY IMPACTS
692,psilocybin,DRUG,mood state,OUTCOME,POSITIVELY IMPACTS
693,Psilocybin,DRUG,amygdala,NEURAL,POSITIVELY IMPACTS
695,Psilocybin,DRUG,increased positive mood state,OUTCOME,POSITIVELY IMPACTS
696,Psilocybin,DRUG,effect on negative mood state,OUTCOME,POSITIVELY IMPACTS
697,Psilocybin,DRUG,psychotropic effects,OUTCOME,POSITIVELY IMPACTS
698,Psilocybin,DRUG,mood state,OUTCOME,POSITIVELY IMPACTS
706,ketanserin,ANTIDEPRESSANT_DRUG,mood state,SUBJECTIVE,POSITIVELY IMPACTS
718,psilocybin,DRUG,5-HT2C blockade,NEURAL,POSITIVELY IMPACTS
738,psilocybin,DRUG,feeling some discernable benefits,OUTCOME,POSITIVELY IMPACTS
739,Psychedelics,DRUG,depression,HEALTH,POSITIVELY IMPACTS
740,Psychedelics,DRUG,drug experiences,OUTCOME,POSITIVELY IMPACTS
741,serotonin receptors,NEURAL,drug experiences,OUTCOME,POSITIVELY IMPACTS
743,psychedelic,DRUG,therapeutic outcomes,OUTCOME,POSITIVELY IMPACTS
744,psychedelic,DRUG,psychological flexibility,OUTCOME,POSITIVELY IMPACTS
747,peyote,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
748,LSD,DRUG,more understanding and acceptance of they and,OUTCOME,POSITIVELY IMPACTS
750,LSD,DRUG,life satisfaction,OUTCOME,POSITIVELY IMPACTS
752,psilocybin,DRUG,improved well-being,OUTCOME,POSITIVELY IMPACTS
753,psilocybin,DRUG,life satisfaction,OUTCOME,POSITIVELY IMPACTS
754,psychedelics,DRUG,life satisfaction,OUTCOME,POSITIVELY IMPACTS
755,psychedelics,DRUG,mescaline,DRUG,POSITIVELY IMPACTS
757,psychedelics,DRUG,suicide attempt,OUTCOME,POSITIVELY IMPACTS
761,peyote,DRUG,depression,HEALTH,POSITIVELY IMPACTS
762,peyote,DRUG,mindfulness,SUBJECTIVE,POSITIVELY IMPACTS
763,peyote,DRUG,suicide attempts,OUTCOME,POSITIVELY IMPACTS
771,LSD,DRUG,suicide attempts,OUTCOME,POSITIVELY IMPACTS
772,psychedelics,DRUG,adverse events,OUTCOME,POSITIVELY IMPACTS
773,psychedelics,DRUG,acceptable safety for clinical use,OUTCOME,POSITIVELY IMPACTS
774,psychedelics,DRUG,death,HEALTH,POSITIVELY IMPACTS
775,psychedelics,DRUG,cultural biases,OUTCOME,POSITIVELY IMPACTS
776,LSD,DRUG,death,HEALTH,POSITIVELY IMPACTS
777,LSD,DRUG,cultural biases,OUTCOME,POSITIVELY IMPACTS
778,LSD,DRUG,beatnik,DRUG,POSITIVELY IMPACTS
780,LSD,DRUG,…,DRUG,POSITIVELY IMPACTS
782,psilocybin,DRUG,"minimal adverse event profile,22,23",OUTCOME,POSITIVELY IMPACTS
783,psilocybin,DRUG,therapeutic advantages,OUTCOME,POSITIVELY IMPACTS
784,psilocybin,DRUG,treatment-resistant depression,HEALTH,POSITIVELY IMPACTS
787,psilocybin,DRUG,alcohol use disorder49,HEALTH,POSITIVELY IMPACTS
788,psilocybin,DRUG,personally meaningful,OUTCOME,POSITIVELY IMPACTS
789,psilocybin,DRUG,insightful experiences,OUTCOME,POSITIVELY IMPACTS
790,psilocybin,DRUG,"large, rapid, and sustained antidepressant effects",OUTCOME,POSITIVELY IMPACTS
793,psilocybin,DRUG,problematic effects,OUTCOME,POSITIVELY IMPACTS
794,psilocybin,DRUG,emergence of psychosis,OUTCOME,POSITIVELY IMPACTS
797,LSD,DRUG,addiction,HEALTH,POSITIVELY IMPACTS
798,ayahuasca,DRUG,mindfulness capacities,OUTCOME,POSITIVELY IMPACTS
799,ayahuasca,DRUG,increase in several mindfulness-related parameters,OUTCOME,POSITIVELY IMPACTS
800,ayahuasca,DRUG,addiction,HEALTH,POSITIVELY IMPACTS
819,ayahuasca,DRUG,acceptance,OUTCOME,POSITIVELY IMPACTS
820,ayahuasca,DRUG,increased self-acceptance,OUTCOME,POSITIVELY IMPACTS
828,ayahuasca,DRUG,advanced-stage cancer patients,HEALTH,POSITIVELY IMPACTS
829,psychedelic 5-HT2A agonists,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
831,psilocybin,DRUG,depressive symptoms,HEALTH,POSITIVELY IMPACTS
836,ayahuasca,DRUG,mindfulness,SUBJECTIVE,POSITIVELY IMPACTS
838,default mode network deactivation,NEURAL,mindfulness,SUBJECTIVE,POSITIVELY IMPACTS
839,ayahuasca,DRUG,transpersonal feelings,SUBJECTIVE,POSITIVELY IMPACTS
841,psychedelics,DRUG,transpersonal feelings,SUBJECTIVE,POSITIVELY IMPACTS
842,psychedelics,DRUG,mindfulness,SUBJECTIVE,POSITIVELY IMPACTS
843,psilocybin,DRUG,mindfulness,SUBJECTIVE,POSITIVELY IMPACTS
845,ayahuasca,DRUG,increases in mindfulness-related capacities,OUTCOME,POSITIVELY IMPACTS
854,psychedelics,DRUG,decreased brain entropy,OUTCOME,POSITIVELY IMPACTS
855,psychedelics,DRUG,entropy,OUTCOME,POSITIVELY IMPACTS
856,psychedelics,DRUG,complexity,OUTCOME,POSITIVELY IMPACTS
857,psychedelics,DRUG,stimulant,DRUG,POSITIVELY IMPACTS
858,psychedelics,DRUG,subjective uncertainty,SUBJECTIVE,POSITIVELY IMPACTS
859,altered states of consciousness,SUBJECTIVE,subjective uncertainty,SUBJECTIVE,POSITIVELY IMPACTS
860,altered states of consciousness,SUBJECTIVE,sense of uncertainty,SUBJECTIVE,POSITIVELY IMPACTS
861,psychedelics,DRUG,sense of uncertainty,SUBJECTIVE,POSITIVELY IMPACTS
862,serotonergic psychedelics,DRUG,sense of uncertainty,SUBJECTIVE,POSITIVELY IMPACTS
863,psychedelics,DRUG,compressibility of signals,OUTCOME,POSITIVELY IMPACTS
864,psychedelics,DRUG,brain entropy,NEURAL,POSITIVELY IMPACTS
865,psychedelics,DRUG,neurobiology of consciousness,NEURAL,POSITIVELY IMPACTS
866,psychedelic,DRUG,neurobiology of consciousness,NEURAL,POSITIVELY IMPACTS
869,consciousness,SUBJECTIVE,integrated-information theory,SUBJECTIVE,POSITIVELY IMPACTS
870,consciousness,SUBJECTIVE,brain entropy,NEURAL,POSITIVELY IMPACTS
871,consciousness,SUBJECTIVE,complexity,OUTCOME,POSITIVELY IMPACTS
872,consciousness,SUBJECTIVE,brain,NEURAL,POSITIVELY IMPACTS
875,consciousness,SUBJECTIVE,entropy,OUTCOME,POSITIVELY IMPACTS
876,integration,SUBJECTIVE,entropy,OUTCOME,POSITIVELY IMPACTS
877,psilocybin,DRUG,attract emotive and often polarised opinions,OUTCOME,POSITIVELY IMPACTS
878,psilocybin,DRUG,depressive disorder,HEALTH,POSITIVELY IMPACTS
879,psilocybin,DRUG,deliverability and cost-effectiveness,OUTCOME,POSITIVELY IMPACTS
881,psychedelics,DRUG,deliverability and cost-effectiveness,OUTCOME,POSITIVELY IMPACTS
882,efficacy,OUTCOME,alcohol dependence,HEALTH,POSITIVELY IMPACTS
883,ayahuasca,DRUG,transient modified state of awareness,OUTCOME,POSITIVELY IMPACTS
884,ayahuasca,DRUG,introspection,OUTCOME,POSITIVELY IMPACTS
885,ayahuasca,DRUG,visions,OUTCOME,POSITIVELY IMPACTS
886,ayahuasca,DRUG,autobiographic and emotional memories,OUTCOME,POSITIVELY IMPACTS
887,ayahuasca,DRUG,positive and valuable,OUTCOME,POSITIVELY IMPACTS
890,ayahuasca,DRUG,receptor,NEURAL,POSITIVELY IMPACTS
911,SR1,NEURAL,receptor,NEURAL,POSITIVELY IMPACTS
912,SR1,NEURAL,depression,HEALTH,POSITIVELY IMPACTS
913,SR1,NEURAL,anxiety,HEALTH,POSITIVELY IMPACTS
917,serotonin reuptake inhibitor,ANTIDEPRESSANT_DRUG,receptor,NEURAL,POSITIVELY IMPACTS
918,serotonin reuptake inhibitor,ANTIDEPRESSANT_DRUG,depression,HEALTH,POSITIVELY IMPACTS
919,serotonin reuptake inhibitor,ANTIDEPRESSANT_DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
922,ayahuasca,DRUG,improvements in mindfulness,OUTCOME,POSITIVELY IMPACTS
923,ayahuasca,DRUG,empowerment,OUTCOME,POSITIVELY IMPACTS
924,ayahuasca,DRUG,hopefulness,OUTCOME,POSITIVELY IMPACTS
925,ayahuasca,DRUG,quality of life-outlook,OUTCOME,POSITIVELY IMPACTS
926,ayahuasca,DRUG,quality of life-meaning,OUTCOME,POSITIVELY IMPACTS
933,ayahuasca,DRUG,improvement in alcohol use,OUTCOME,POSITIVELY IMPACTS
934,ayahuasca,DRUG,cessation of drug use,OUTCOME,POSITIVELY IMPACTS
939,ayahuasca,DRUG,reductions in associated symptomatology,OUTCOME,POSITIVELY IMPACTS
941,ayahuasca,DRUG,panic- and hopelessness-related states,OUTCOME,POSITIVELY IMPACTS
942,ayahuasca,DRUG,Depression,HEALTH,POSITIVELY IMPACTS
949,LSD,DRUG,elevated brain-wide shared signal,OUTCOME,POSITIVELY IMPACTS
950,LSD,DRUG,brain-wide hyper-connectivity,NEURAL,POSITIVELY IMPACTS
951,ayahuasca,DRUG,elevated brain-wide shared signal,OUTCOME,POSITIVELY IMPACTS
952,ayahuasca,DRUG,hypo-connectivity,OUTCOME,POSITIVELY IMPACTS
953,ayahuasca,DRUG,brain-wide hyper-connectivity,NEURAL,POSITIVELY IMPACTS
957,psilocybin,DRUG,hypo-connectivity,OUTCOME,POSITIVELY IMPACTS
958,psilocybin,DRUG,brain-wide hyper-connectivity,NEURAL,POSITIVELY IMPACTS
961,LSD,DRUG,hypo-connectivity,OUTCOME,POSITIVELY IMPACTS
962,LSD,DRUG,amygdala,NEURAL,POSITIVELY IMPACTS
964,LSD,DRUG,alterations in amygdala activity and connectivity,OUTCOME,POSITIVELY IMPACTS
965,LSD,DRUG,beneficial clinical effects,OUTCOME,POSITIVELY IMPACTS
966,LSD,DRUG,de-coupling in associative networks,OUTCOME,POSITIVELY IMPACTS
967,LSD,DRUG,systems-level perturbations,NEURAL,POSITIVELY IMPACTS
968,LSD,DRUG,hyper-and hypo-connectivity,OUTCOME,POSITIVELY IMPACTS
969,LSD,DRUG,altered state of consciousness,SUBJECTIVE,POSITIVELY IMPACTS
982,LSD,DRUG,negligible changes,OUTCOME,POSITIVELY IMPACTS
983,Pla,DRUG,negligible changes,OUTCOME,POSITIVELY IMPACTS
984,Ketanserin,DRUG,negligible changes,OUTCOME,POSITIVELY IMPACTS
986,Pla,DRUG,brain-wide dysconnectivity,NEURAL,POSITIVELY IMPACTS
988,LSD,DRUG,sensory networks,NEURAL,POSITIVELY IMPACTS
990,LSD,DRUG,brain-wide net effect,NEURAL,POSITIVELY IMPACTS
992,LSD,DRUG,brain-wide dysconnectivity,NEURAL,POSITIVELY IMPACTS
993,Ketanserin,DRUG,sensory networks,NEURAL,POSITIVELY IMPACTS
994,Ketanserin,DRUG,hypo-connectivity,OUTCOME,POSITIVELY IMPACTS
995,Ketanserin,DRUG,brain-wide net effect,NEURAL,POSITIVELY IMPACTS
997,Ketanserin,DRUG,brain-wide dysconnectivity,NEURAL,POSITIVELY IMPACTS
1002,LSD,DRUG,alterations in neural and behavioral effects,OUTCOME,POSITIVELY IMPACTS
1004,LSD,DRUG,brain-wide integration of sensory networks,NEURAL,POSITIVELY IMPACTS
1007,LSD,DRUG,neural and behavioral alterations,OUTCOME,POSITIVELY IMPACTS
1012,LSD,DRUG,cortices,NEURAL,POSITIVELY IMPACTS
1018,LSD,DRUG,hyper- and hypo-connectivity change scores,OUTCOME,POSITIVELY IMPACTS
1019,LSD,DRUG,hyper-connectivity,NEURAL,POSITIVELY IMPACTS
1020,LSD,DRUG,functionally pre-defined networks,NEURAL,POSITIVELY IMPACTS
1024,LSD,DRUG,bi-directional brain-wide shared signal,OUTCOME,POSITIVELY IMPACTS
1027,LSD,DRUG,Ket,DRUG,POSITIVELY IMPACTS
1028,LSD,DRUG,subjective drug effects,OUTCOME,POSITIVELY IMPACTS
1029,LSD,DRUG,subjectively accessible,OUTCOME,POSITIVELY IMPACTS
1030,LSD,DRUG,blissful state,SUBJECTIVE,POSITIVELY IMPACTS
1031,LSD,DRUG,higher subjective effects,OUTCOME,POSITIVELY IMPACTS
1036,LSD,DRUG,postcentral gyrus,NEURAL,POSITIVELY IMPACTS
1042,Pla,DRUG,subjectively accessible,OUTCOME,POSITIVELY IMPACTS
1043,Pla,DRUG,blissful state,SUBJECTIVE,POSITIVELY IMPACTS
1044,Pla,DRUG,postcentral gyrus,NEURAL,POSITIVELY IMPACTS
1051,GBC,NEURAL,blissful state,SUBJECTIVE,POSITIVELY IMPACTS
1053,psychedelic,DRUG,sense of self,SUBJECTIVE,POSITIVELY IMPACTS
1054,LSD,DRUG,sense of self,SUBJECTIVE,POSITIVELY IMPACTS
1055,consciousness,SUBJECTIVE,sense of self,SUBJECTIVE,POSITIVELY IMPACTS
1056,sensorimotor system,NEURAL,sense of self,SUBJECTIVE,POSITIVELY IMPACTS
1058,psychedelic,DRUG,delusions,HEALTH,POSITIVELY IMPACTS
1059,psychedelic,DRUG,alterations in the sense of self,OUTCOME,POSITIVELY IMPACTS
1061,LSD,DRUG,delusions,HEALTH,POSITIVELY IMPACTS
1062,LSD,DRUG,alterations in the sense of self,OUTCOME,POSITIVELY IMPACTS
1065,LSD,DRUG,neuronal and subjective effects,OUTCOME,POSITIVELY IMPACTS
1075,LSD,DRUG,HTR2C,NEURAL,POSITIVELY IMPACTS
1078,ayahuasca,DRUG,creativity,OUTCOME,POSITIVELY IMPACTS
1083,ayahuasca,DRUG,enhancement of divergent thinking,OUTCOME,POSITIVELY IMPACTS
1090,ayahuasca,DRUG,mescaline,DRUG,POSITIVELY IMPACTS
1095,ayahuasca,DRUG,associations and insights,OUTCOME,POSITIVELY IMPACTS
1097,ayahuasca,DRUG,cognitive flexibility,OUTCOME,POSITIVELY IMPACTS
1098,ayahuasca,DRUG,enhanced divergent thinking,OUTCOME,POSITIVELY IMPACTS
1100,ayahuasca,DRUG,placebo state,SUBJECTIVE,POSITIVELY IMPACTS
1101,psilocybin,DRUG,cognitive flexibility,OUTCOME,POSITIVELY IMPACTS
1104,psychedelics,DRUG,more novel thoughts,OUTCOME,POSITIVELY IMPACTS
1117,ayahuasca,DRUG,mindfulness-related capacities were enhanced,OUTCOME,POSITIVELY IMPACTS
1119,ayahuasca,DRUG,post-traumatic stress disorder,HEALTH,POSITIVELY IMPACTS
1122,psychedelics,DRUG,therapeutic process,OUTCOME,POSITIVELY IMPACTS
1123,ayahuasca,DRUG,therapeutic process,OUTCOME,POSITIVELY IMPACTS
1125,Psilocybin,DRUG,psychological distress,HEALTH,POSITIVELY IMPACTS
1126,Psilocybin,DRUG,psychiatric conditions,HEALTH,POSITIVELY IMPACTS
1127,psilocybin,DRUG,single mediating factor,OUTCOME,POSITIVELY IMPACTS
1129,psilocybin,DRUG,deeply meaningful attachments to important family members and significant others,OUTCOME,POSITIVELY IMPACTS
1130,psilocybin,DRUG,forgiveness of others,OUTCOME,POSITIVELY IMPACTS
1131,psilocybin,DRUG,loved ones as spirit guides,OUTCOME,POSITIVELY IMPACTS
1132,psilocybin,DRUG,narrating one’s experience with loved ones,OUTCOME,POSITIVELY IMPACTS
1133,psilocybin,DRUG,improved relationships posttreatment,OUTCOME,POSITIVELY IMPACTS
1146,psilocybin,DRUG,"feelings of relief, wholeness, freedom, and affirmation",OUTCOME,POSITIVELY IMPACTS
1149,"surrender or “let go,”",OUTCOME,"feelings of relief, wholeness, freedom, and affirmation",OUTCOME,POSITIVELY IMPACTS
1150,psilocybin,DRUG,experienced profound emotional depths,OUTCOME,POSITIVELY IMPACTS
1151,psilocybin,DRUG,expanded affective boundaries,OUTCOME,POSITIVELY IMPACTS
1152,psilocybin,DRUG,visions,OUTCOME,POSITIVELY IMPACTS
1153,psilocybin,DRUG,deeply coded with layers of meaning,OUTCOME,POSITIVELY IMPACTS
1154,psilocybin,DRUG,lasting impacts to study participants quality of life,OUTCOME,POSITIVELY IMPACTS
1155,psilocybin,DRUG,life priorities,OUTCOME,POSITIVELY IMPACTS
1156,psilocybin,DRUG,sense of identity,OUTCOME,POSITIVELY IMPACTS
1157,psilocybin,DRUG,recovered a sense of what is most important and vital,OUTCOME,POSITIVELY IMPACTS
1158,psilocybin,DRUG,being present in the moment,OUTCOME,POSITIVELY IMPACTS
1159,psilocybin,DRUG,kind to other people,OUTCOME,POSITIVELY IMPACTS
1160,psilocybin,DRUG,feeling “reborn,OUTCOME,POSITIVELY IMPACTS
1161,psilocybin,DRUG,more expansive,OUTCOME,POSITIVELY IMPACTS
1162,psilocybin,DRUG,more confident,OUTCOME,POSITIVELY IMPACTS
1163,psilocybin,DRUG,more connected,OUTCOME,POSITIVELY IMPACTS
1164,psilocybin,DRUG,more alive,OUTCOME,POSITIVELY IMPACTS
1165,psilocybin,DRUG,feeling of empowerment,OUTCOME,POSITIVELY IMPACTS
1170,psilocybin,DRUG,lasting impacts,OUTCOME,POSITIVELY IMPACTS
1171,psilocybin,DRUG,death,HEALTH,POSITIVELY IMPACTS
1172,psilocybin,DRUG,spirituality,SUBJECTIVE,POSITIVELY IMPACTS
1173,psilocybin,DRUG,cancer patients,HEALTH,POSITIVELY IMPACTS
1174,psilocybin,DRUG,existential and psychological distress,OUTCOME,POSITIVELY IMPACTS
1176,psilocybin,DRUG,relationally embedded,OUTCOME,POSITIVELY IMPACTS
1177,psilocybin,DRUG,deeply meaningful,OUTCOME,POSITIVELY IMPACTS
1178,psilocybin,DRUG,biographically instantiated,OUTCOME,POSITIVELY IMPACTS
1179,psilocybin,DRUG,lasting impacts to Participants experience of Participants and the world,OUTCOME,POSITIVELY IMPACTS
1180,psilocybin,DRUG,cancer,HEALTH,POSITIVELY IMPACTS
1190,psilocybin,DRUG,maximize therapeutic benefit,OUTCOME,POSITIVELY IMPACTS
1192,psilocybin,DRUG,medical and public health significance,OUTCOME,POSITIVELY IMPACTS
1193,psilocybin,DRUG,potential therapeutic benefits,OUTCOME,POSITIVELY IMPACTS
1199,psilocybin,DRUG,science does not support scheduling more restrictive than IV,OUTCOME,POSITIVELY IMPACTS
1200,psilocybin,DRUG,profound and very long lasting positive changes in mood and well-being,OUTCOME,POSITIVELY IMPACTS
1201,psilocybin,DRUG,treatment resistant mental and behavioral disorders,HEALTH,POSITIVELY IMPACTS
1203,psilocybin,DRUG,the need for such research is urgent,OUTCOME,POSITIVELY IMPACTS
1205,psychedelics,DRUG,profound and very long lasting positive changes in mood and well-being,OUTCOME,POSITIVELY IMPACTS
1209,LSD,DRUG,neuronal populations,NEURAL,POSITIVELY IMPACTS
1210,LSD,DRUG,highly interrelated processes,OUTCOME,POSITIVELY IMPACTS
1211,LSD,DRUG,disruption of established neural connectivity,OUTCOME,POSITIVELY IMPACTS
1212,LSD,DRUG,emergence of novel functional associations,OUTCOME,POSITIVELY IMPACTS
1213,psilocybin,DRUG,neuronal populations,NEURAL,POSITIVELY IMPACTS
1214,psilocybin,DRUG,highly interrelated processes,OUTCOME,POSITIVELY IMPACTS
1215,psilocybin,DRUG,disruption of established neural connectivity,OUTCOME,POSITIVELY IMPACTS
1216,psilocybin,DRUG,emergence of novel functional associations,OUTCOME,POSITIVELY IMPACTS
1228,psychedelic,DRUG,brain regions,NEURAL,POSITIVELY IMPACTS
1229,psychedelic,DRUG,different transcriptional responses,OUTCOME,POSITIVELY IMPACTS
1232,compounds,DRUG,brain regions,NEURAL,POSITIVELY IMPACTS
1234,compounds,DRUG,addiction,HEALTH,POSITIVELY IMPACTS
1235,compounds,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
1240,psychedelic drugs,DRUG,addiction,HEALTH,POSITIVELY IMPACTS
1241,psychedelic drugs,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
1243,harmine,DRUG,stimulated the proliferation and migration of progenitor cells,OUTCOME,POSITIVELY IMPACTS
1244,harmine,DRUG,promoted progenitor cells differentiation,OUTCOME,POSITIVELY IMPACTS
1246,THH,DRUG,stimulated the proliferation and migration of progenitor cells,OUTCOME,POSITIVELY IMPACTS
1247,THH,DRUG,promoted progenitor cells differentiation,OUTCOME,POSITIVELY IMPACTS
1249,harmaline,DRUG,stimulated the proliferation and migration of progenitor cells,OUTCOME,POSITIVELY IMPACTS
1250,harmaline,DRUG,promoted progenitor cells differentiation,OUTCOME,POSITIVELY IMPACTS
1252,ayahuasca,DRUG,stimulated the proliferation and migration of progenitor cells,OUTCOME,POSITIVELY IMPACTS
1253,ayahuasca,DRUG,promoted progenitor cells differentiation,OUTCOME,POSITIVELY IMPACTS
1255,SVZ,NEURAL,stimulated the proliferation and migration of progenitor cells,OUTCOME,POSITIVELY IMPACTS
1256,SVZ,NEURAL,promoted progenitor cells differentiation,OUTCOME,POSITIVELY IMPACTS
1257,SGZ,NEURAL,stimulated the proliferation and migration of progenitor cells,OUTCOME,POSITIVELY IMPACTS
1258,SGZ,NEURAL,promoted progenitor cells differentiation,OUTCOME,POSITIVELY IMPACTS
1267,compounds,DRUG,cellular differentiation,OUTCOME,POSITIVELY IMPACTS
1268,compounds,DRUG,Tuj-1,NEURAL,POSITIVELY IMPACTS
1269,compounds,DRUG,equally expressed,OUTCOME,POSITIVELY IMPACTS
1270,compounds,DRUG,Tuj-1 levels,NEURAL,POSITIVELY IMPACTS
1276,compounds,DRUG,stimulated migration,OUTCOME,POSITIVELY IMPACTS
1277,compounds,DRUG,promote the three processes involved in full adult neurogenesis,OUTCOME,POSITIVELY IMPACTS
1279,Lmx1a,NEURAL,promote the three processes involved in full adult neurogenesis,OUTCOME,POSITIVELY IMPACTS
1280,Lmx1b44,NEURAL,stimulated migration,OUTCOME,POSITIVELY IMPACTS
1281,Lmx1b44,NEURAL,promote the three processes involved in full adult neurogenesis,OUTCOME,POSITIVELY IMPACTS
1286,THH,DRUG,promote the three processes involved in full adult neurogenesis,OUTCOME,POSITIVELY IMPACTS
1288,serotonin depletion,NEURAL,harmol,DRUG,POSITIVELY IMPACTS
1289,serotonin depletion,NEURAL,fluoxetine,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
1290,serotonin depletion,NEURAL,imipramine,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
1291,serotonin depletion,NEURAL,hippocampal neurogenesis,OUTCOME,POSITIVELY IMPACTS
1292,serotonin depletion,NEURAL,human neural progenitor cells,NEURAL,POSITIVELY IMPACTS
1293,molecules,NEURAL,hippocampal neurogenesis,OUTCOME,POSITIVELY IMPACTS
1294,molecules,NEURAL,human neural progenitor cells,NEURAL,POSITIVELY IMPACTS
1295,molecules,NEURAL,endothelial growth,NEURAL,POSITIVELY IMPACTS
1296,molecules,NEURAL,relevant therapeutic implications,OUTCOME,POSITIVELY IMPACTS
1297,serotonin reuptake inhibitor fluoxetine,ANTIDEPRESSANT_DRUG,endothelial growth,NEURAL,POSITIVELY IMPACTS
1298,serotonin reuptake inhibitor fluoxetine,ANTIDEPRESSANT_DRUG,increases neurogenesis,OUTCOME,POSITIVELY IMPACTS
1299,serotonin reuptake inhibitor fluoxetine,ANTIDEPRESSANT_DRUG,imipramine,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
1300,selective MAO-A inhibitor pirlindole53,ANTIDEPRESSANT_DRUG,increases neurogenesis,OUTCOME,POSITIVELY IMPACTS
1301,selective MAO-A inhibitor pirlindole53,ANTIDEPRESSANT_DRUG,imipramine,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
1302,SGZ,NEURAL,increases neurogenesis,OUTCOME,POSITIVELY IMPACTS
1303,SGZ,NEURAL,imipramine,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
1304,fluoxetine,ANTIDEPRESSANT_DRUG,imipramine,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
1307,ayahuasca,DRUG,imipramine,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
1308,ayahuasca,DRUG,"neuropsychiatric disorders60,61,62",HEALTH,POSITIVELY IMPACTS
1309,ayahuasca,DRUG,decreases in problematic alcohol,OUTCOME,POSITIVELY IMPACTS
1310,ayahuasca,DRUG,cocaine and opiate consumption,OUTCOME,POSITIVELY IMPACTS
1311,ayahuasca,DRUG,anti-addiction properties,OUTCOME,POSITIVELY IMPACTS
1318,profound psychological experiences,OUTCOME,improves behavioral measures of depression17,OUTCOME,POSITIVELY IMPACTS
1319,profound psychological experiences,OUTCOME,behavioral improvement,OUTCOME,POSITIVELY IMPACTS
1324,harmine,DRUG,improves behavioral measures of depression17,OUTCOME,POSITIVELY IMPACTS
1325,harmine,DRUG,neurogenesis,OUTCOME,POSITIVELY IMPACTS
1326,harmine,DRUG,behavioral improvement,OUTCOME,POSITIVELY IMPACTS
1327,MAO inhibitors,ANTIDEPRESSANT_DRUG,brain plasticity,NEURAL,POSITIVELY IMPACTS
1328,ayahuasca,DRUG,brain plasticity,NEURAL,POSITIVELY IMPACTS
1329,ayahuasca,DRUG,neurologic disorders,HEALTH,POSITIVELY IMPACTS
1332,compounds,DRUG,brain plasticity,NEURAL,POSITIVELY IMPACTS
1333,compounds,DRUG,neurologic disorders,HEALTH,POSITIVELY IMPACTS
1339,psychedelic,DRUG,stimulation of mood,OUTCOME,POSITIVELY IMPACTS
1342,psychedelic “,DRUG,mood,SUBJECTIVE,POSITIVELY IMPACTS
1343,psilocybin,DRUG,enhanced creativity,OUTCOME,POSITIVELY IMPACTS
1346,psilocybin,DRUG,decrease in cerebral 5-HT levels,OUTCOME,POSITIVELY IMPACTS
1347,psilocybin,DRUG,underestimation of occupancy,OUTCOME,POSITIVELY IMPACTS
1350,ayahuasca,DRUG,anxiolytic and antidepressive properties,OUTCOME,POSITIVELY IMPACTS
1351,ayahuasca,DRUG,reduced psychopathology,OUTCOME,POSITIVELY IMPACTS
1352,ayahuasca,DRUG,anxiolytic and antidepressive effects,OUTCOME,POSITIVELY IMPACTS
1356,these compounds,DRUG,anxiolytic and antidepressive properties,OUTCOME,POSITIVELY IMPACTS
1357,these compounds,DRUG,reduced psychopathology,OUTCOME,POSITIVELY IMPACTS
1358,these compounds,DRUG,depression,HEALTH,POSITIVELY IMPACTS
1361,ayahuasca,DRUG,do not exhibit symptoms of psychiatric disorders or neurocognitive problems,OUTCOME,POSITIVELY IMPACTS
1362,ayahuasca,DRUG,better cognitive function,OUTCOME,POSITIVELY IMPACTS
1363,ayahuasca,DRUG,increased well-being and spirituality,OUTCOME,POSITIVELY IMPACTS
1367,ayahuasca,DRUG,"MAO-A inhibitor,3,5",NEURAL,POSITIVELY IMPACTS
1376,harmaline,DRUG,reduced psychopathology,OUTCOME,POSITIVELY IMPACTS
1377,harmaline,DRUG,depression,HEALTH,POSITIVELY IMPACTS
1378,hallucinogens,DRUG,emotional processing,OUTCOME,POSITIVELY IMPACTS
1383,harmine,DRUG,emotional processing,OUTCOME,POSITIVELY IMPACTS
1388,THH,DRUG,emotional processing,OUTCOME,POSITIVELY IMPACTS
1389,THH,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
1390,THH,DRUG,depressive symptoms,OUTCOME,POSITIVELY IMPACTS
1391,THH,DRUG,mood,OUTCOME,POSITIVELY IMPACTS
1392,5-HT1A/2A/2C receptor agonists,NEURAL,emotional processing,OUTCOME,POSITIVELY IMPACTS
1393,5-HT1A/2A/2C receptor agonists,NEURAL,anxiety,HEALTH,POSITIVELY IMPACTS
1394,5-HT1A/2A/2C receptor agonists,NEURAL,depressive symptoms,OUTCOME,POSITIVELY IMPACTS
1395,5-HT1A/2A/2C receptor agonists,NEURAL,mood,OUTCOME,POSITIVELY IMPACTS
1396,5-HT1A/2A/2C receptor,NEURAL,depressive symptoms,HEALTH,POSITIVELY IMPACTS
1403,LSD,DRUG,depressive symptoms,HEALTH,POSITIVELY IMPACTS
1409,OCDs,HEALTH,anxiety,HEALTH,POSITIVELY IMPACTS
1410,OCDs,HEALTH,depressive symptoms,HEALTH,POSITIVELY IMPACTS
1411,OCDs,HEALTH,mood,OUTCOME,POSITIVELY IMPACTS
1412,psilocybin,DRUG,neurosis,HEALTH,POSITIVELY IMPACTS
1413,psilocybin,DRUG,OCDs,HEALTH,POSITIVELY IMPACTS
1414,psilocybin,DRUG,anxiolytic effects,OUTCOME,POSITIVELY IMPACTS
1415,psilocybin-,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
1417,psilocybin-,DRUG,depression,HEALTH,POSITIVELY IMPACTS
1418,psilocybin-,DRUG,cancer,HEALTH,POSITIVELY IMPACTS
1423,ayahuasca,DRUG,significantly reduced DMN activation.73,OUTCOME,POSITIVELY IMPACTS
1426,serotonergic hallucinogens,DRUG,significantly reduced DMN activation.73,OUTCOME,POSITIVELY IMPACTS
1429,PCC,NEURAL,significantly reduced DMN activation.73,OUTCOME,POSITIVELY IMPACTS
1431,hallucinogens,DRUG,anxiolytic and antidepressive effects,OUTCOME,POSITIVELY IMPACTS
1433,ayahuasca,DRUG,meditative states,SUBJECTIVE,POSITIVELY IMPACTS
1438,ayahuasca,DRUG,depressive disorders,HEALTH,POSITIVELY IMPACTS
1444,ayahuasca,DRUG,depressed patients,HEALTH,POSITIVELY IMPACTS
1457,LSD,DRUG,cluster headaches,HEALTH,POSITIVELY IMPACTS
1462,psilocybin,DRUG,cluster headaches,HEALTH,POSITIVELY IMPACTS
1467,microdosing,DRUG,decreased depression,OUTCOME,POSITIVELY IMPACTS
1468,microdosing,DRUG,stress,HEALTH,POSITIVELY IMPACTS
1469,microdosing,DRUG,immediate boost,OUTCOME,POSITIVELY IMPACTS
1470,microdosing,DRUG,increased absorption,OUTCOME,POSITIVELY IMPACTS
1475,psilocybin,DRUG,Extraversion and Openness scores significantly increased,OUTCOME,POSITIVELY IMPACTS
1477,psilocybin,DRUG,changes of personality traits,OUTCOME,POSITIVELY IMPACTS
1478,psilocybin,DRUG,Conscientiousness only at trend-level,OUTCOME,POSITIVELY IMPACTS
1479,psychedelic,DRUG,depressed individuals,HEALTH,POSITIVELY IMPACTS
1480,moclobemide,ANTIDEPRESSANT_DRUG,Conscientiousness,OUTCOME,POSITIVELY IMPACTS
1481,SSRIs,ANTIDEPRESSANT_DRUG,personality,SUBJECTIVE,POSITIVELY IMPACTS
1482,psychedelics,DRUG,personality,SUBJECTIVE,POSITIVELY IMPACTS
1483,psychedelics,DRUG,long-lasting increases in trait Openness,OUTCOME,POSITIVELY IMPACTS
1485,LSD,DRUG,long-lasting increases in trait Openness,OUTCOME,POSITIVELY IMPACTS
1486,LSD,DRUG,post-traumatic stress disorder,HEALTH,POSITIVELY IMPACTS
1489,psychedelic,DRUG,post-traumatic stress disorder,HEALTH,POSITIVELY IMPACTS
1490,Neuroticism,NEURAL,Extraversion,OUTCOME,POSITIVELY IMPACTS
1491,Neuroticism,NEURAL,Openness,OUTCOME,POSITIVELY IMPACTS
1492,psychedelic,DRUG,Openness,OUTCOME,POSITIVELY IMPACTS
1493,psychedelic,DRUG,higher Openness,OUTCOME,POSITIVELY IMPACTS
1494,psychedelic,DRUG,lasting changes in personality,OUTCOME,POSITIVELY IMPACTS
1495,psychedelic,DRUG,subtle drop in Openness and Extraversion scores,OUTCOME,POSITIVELY IMPACTS
1496,religious conversion,SUBJECTIVE,outlook,SUBJECTIVE,POSITIVELY IMPACTS
1497,spiritual experience,OUTCOME,outlook,SUBJECTIVE,POSITIVELY IMPACTS
1498,spiritual experience,OUTCOME,long-lasting impact,OUTCOME,POSITIVELY IMPACTS
1499,mystical experience,SUBJECTIVE,blissful state,SUBJECTIVE,POSITIVELY IMPACTS
1502,psilocybin,DRUG,self-consciousness,SUBJECTIVE,POSITIVELY IMPACTS
1506,DMT,DRUG,elevated Openness,OUTCOME,POSITIVELY IMPACTS
1507,LSD,DRUG,elevated Openness,OUTCOME,POSITIVELY IMPACTS
1508,LSD,DRUG,changes in Openness,OUTCOME,POSITIVELY IMPACTS
1509,LSD,DRUG,changes in personality measures,OUTCOME,POSITIVELY IMPACTS
1511,psychedelic,DRUG,increases in Conscientiousness,OUTCOME,POSITIVELY IMPACTS
1512,psilocybin,DRUG,increases in Conscientiousness,OUTCOME,POSITIVELY IMPACTS
1513,psilocybin,DRUG,pronounced increases in Extraversion,OUTCOME,POSITIVELY IMPACTS
1514,psilocybin,DRUG,Insight,SUBJECTIVE,POSITIVELY IMPACTS
1515,psychedelic,DRUG,enhanced mindfulness capacities,OUTCOME,POSITIVELY IMPACTS
1516,psychedelic,DRUG,decreased judgmental and reactive attitudes,OUTCOME,POSITIVELY IMPACTS
1517,ayahuasca,DRUG,enhanced mindfulness capacities,OUTCOME,POSITIVELY IMPACTS
1518,ayahuasca,DRUG,decreased judgmental and reactive attitudes,OUTCOME,POSITIVELY IMPACTS
1519,ayahuasca,DRUG,Mindsens,NEURAL,POSITIVELY IMPACTS
1520,Ayahuasca,DRUG,enhanced mindfulness capacities,OUTCOME,POSITIVELY IMPACTS
1521,Ayahuasca,DRUG,decreased judgmental and reactive attitudes,OUTCOME,POSITIVELY IMPACTS
1522,NAAG,NEURAL,decrease of alpha oscillations,OUTCOME,POSITIVELY IMPACTS
1523,ayahuasca,DRUG,Glx,NEURAL,POSITIVELY IMPACTS
1524,ayahuasca,DRUG,clinical improvement,OUTCOME,POSITIVELY IMPACTS
1526,Psychedelics,DRUG,clinical improvement,OUTCOME,POSITIVELY IMPACTS
1528,Psychedelics,DRUG,personal sense of “self,SUBJECTIVE,POSITIVELY IMPACTS
1529,Psychedelics,DRUG,increase in coupling,OUTCOME,POSITIVELY IMPACTS
1530,psilocybin,DRUG,enhanced mindfulness capacities,OUTCOME,POSITIVELY IMPACTS
1531,LSD,DRUG,increase in coupling,OUTCOME,POSITIVELY IMPACTS
1532,LSD,DRUG,enhanced mindfulness capacities,OUTCOME,POSITIVELY IMPACTS
1533,LSD,DRUG,reduced judgmental processing,OUTCOME,POSITIVELY IMPACTS
1534,LSD,DRUG,increased self-kindness,OUTCOME,POSITIVELY IMPACTS
1535,psilocybin,DRUG,limbic structures,NEURAL,POSITIVELY IMPACTS
1537,ayahuasca,DRUG,limbic structures,NEURAL,POSITIVELY IMPACTS
1538,modification induced by psychedelics,OUTCOME,limbic structures,NEURAL,POSITIVELY IMPACTS
1540,psychedelic,DRUG,brain plasticity,NEURAL,POSITIVELY IMPACTS
1541,psychedelic,DRUG,increases in trait openness,OUTCOME,POSITIVELY IMPACTS
1542,ayahuasca,DRUG,increases in trait openness,OUTCOME,POSITIVELY IMPACTS
1543,ayahuasca,DRUG,increased self-transcendence,OUTCOME,POSITIVELY IMPACTS
1544,ayahuasca,DRUG,brain dynamics,NEURAL,POSITIVELY IMPACTS
1545,ayahuasca,DRUG,addiction disorders,HEALTH,POSITIVELY IMPACTS
1546,ayahuasca,DRUG,self-centeredness,SUBJECTIVE,POSITIVELY IMPACTS
1551,ayahuasca,DRUG,brain function,NEURAL,POSITIVELY IMPACTS
1566,ayahuasca,DRUG,enhanced mindfulness facets,OUTCOME,POSITIVELY IMPACTS
1567,psilocybin,DRUG,a sense of grounding,OUTCOME,POSITIVELY IMPACTS
1569,psilocybin,DRUG,…,DRUG,POSITIVELY IMPACTS
1570,…,DRUG,…,DRUG,POSITIVELY IMPACTS
1571,misguidance,DRUG,dissonance,DRUG,POSITIVELY IMPACTS
1572,psilocybin,DRUG,"liking, resonance, and openness",OUTCOME,POSITIVELY IMPACTS
1573,psilocybin,DRUG,reported insightfulness,OUTCOME,POSITIVELY IMPACTS
1574,psilocybin,DRUG,insightfulness,SUBJECTIVE,POSITIVELY IMPACTS
1575,psilocybin,DRUG,promote the occurrence of therapeutically meaningful experiences,OUTCOME,POSITIVELY IMPACTS
1576,psilocybin,DRUG,sustained positive changes in behaviour and personality,OUTCOME,POSITIVELY IMPACTS
1581,drug effect,OUTCOME,depression,HEALTH,POSITIVELY IMPACTS
1582,psychedelics,DRUG,deeply felt and personally meaningful emotionality,OUTCOME,POSITIVELY IMPACTS
1583,music,DRUG,deeply felt and personally meaningful emotionality,OUTCOME,POSITIVELY IMPACTS
1584,intense emotional experiences,OUTCOME,deeply felt and personally meaningful emotionality,OUTCOME,POSITIVELY IMPACTS
1585,dislike,OUTCOME,sense of being on a journey,SUBJECTIVE,POSITIVELY IMPACTS
1586,psilocybin,DRUG,paranoia,OUTCOME,POSITIVELY IMPACTS
1587,psilocybin,DRUG,meaningful and spiritually significant experiences,OUTCOME,POSITIVELY IMPACTS
1589,psilocybin,DRUG,egodissolution,SUBJECTIVE,POSITIVELY IMPACTS
1590,psilocybin,DRUG,addiction treatment,HEALTH,POSITIVELY IMPACTS
1591,unity experience,SUBJECTIVE,sense of sanity,SUBJECTIVE,POSITIVELY IMPACTS
1592,serotonergic hallucinogens,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
1593,serotonergic hallucinogens,DRUG,mood,HEALTH,POSITIVELY IMPACTS
1594,serotonergic hallucinogens,DRUG,anxiolytic,OUTCOME,POSITIVELY IMPACTS
1595,serotonergic hallucinogens,DRUG,antidepressive,OUTCOME,POSITIVELY IMPACTS
1596,serotonergic hallucinogens,DRUG,antiaddictive,OUTCOME,POSITIVELY IMPACTS
1598,psychedelics,DRUG,mood,HEALTH,POSITIVELY IMPACTS
1599,psychedelics,DRUG,anxiolytic,OUTCOME,POSITIVELY IMPACTS
1600,psychedelics,DRUG,antiaddictive,OUTCOME,POSITIVELY IMPACTS
1609,LSD,DRUG,anxiolytic,OUTCOME,POSITIVELY IMPACTS
1611,LSD,DRUG,alcohol dependence,HEALTH,POSITIVELY IMPACTS
1614,psilocybin,DRUG,anxiolytic,OUTCOME,POSITIVELY IMPACTS
1615,psilocybin,DRUG,antidepressive,OUTCOME,POSITIVELY IMPACTS
1617,psilocybin,DRUG,alcohol dependence,HEALTH,POSITIVELY IMPACTS
1618,psilocybin,DRUG,anxiolytic and antidepressive effects,OUTCOME,POSITIVELY IMPACTS
1619,psilocybin,DRUG,advanced-stage cancer,HEALTH,POSITIVELY IMPACTS
1624,LSD,DRUG,existential anxiety,HEALTH,POSITIVELY IMPACTS
1636,alcoholism,DRUG,depression,HEALTH,POSITIVELY IMPACTS
1659,psilocybin,DRUG,rapid (24 h),OUTCOME,POSITIVELY IMPACTS
1660,psilocybin,DRUG,therapeutic effects,OUTCOME,POSITIVELY IMPACTS
1661,psilocybin,DRUG,antiaddictive effects,OUTCOME,POSITIVELY IMPACTS
1665,ayahuasca,DRUG,rapid (24 h),OUTCOME,POSITIVELY IMPACTS
1666,ayahuasca,DRUG,therapeutic effects,OUTCOME,POSITIVELY IMPACTS
1667,ayahuasca,DRUG,antiaddictive effects,OUTCOME,POSITIVELY IMPACTS
1671,LSD,DRUG,antiaddictive effects,OUTCOME,POSITIVELY IMPACTS
1674,LSD,DRUG,reduced impulsivity,OUTCOME,POSITIVELY IMPACTS
1675,LSD,DRUG,novelty seeking,OUTCOME,POSITIVELY IMPACTS
1681,ayahuasca,DRUG,anxiolytic,OUTCOME,POSITIVELY IMPACTS
1687,ayahuasca,DRUG,stress,OUTCOME,POSITIVELY IMPACTS
1689,convergent thinking,OUTCOME,mindfulness,SUBJECTIVE,POSITIVELY IMPACTS
1699,Antidepressant properties,OUTCOME,mindfulness,SUBJECTIVE,POSITIVELY IMPACTS
1700,ayahuasca,DRUG,satisfaction with life,OUTCOME,POSITIVELY IMPACTS
1707,MAO-A inhibitors,NEURAL,mindfulness,SUBJECTIVE,POSITIVELY IMPACTS
1709,harmaline,DRUG,hippocampal progenitor cells,NEURAL,POSITIVELY IMPACTS
1710,harmaline,DRUG,Neurogenesis,OUTCOME,POSITIVELY IMPACTS
1711,psychedelic compounds,DRUG,hippocampal progenitor cells,NEURAL,POSITIVELY IMPACTS
1712,psychedelic compounds,DRUG,synaptic plasticity,NEURAL,POSITIVELY IMPACTS
1713,psychedelic compounds,DRUG,Neurogenesis,OUTCOME,POSITIVELY IMPACTS
1717,ayahuasca,DRUG,changes in mindfulness,OUTCOME,POSITIVELY IMPACTS
1722,ayahuasca,DRUG,modified state of consciousness,SUBJECTIVE,POSITIVELY IMPACTS
1723,PCT performance,OUTCOME,mindfulness,SUBJECTIVE,POSITIVELY IMPACTS
1725,psychedelic,DRUG,mindfulness,SUBJECTIVE,POSITIVELY IMPACTS
1730,ayahuasca,DRUG,stronger reductions in symptoms of depression,OUTCOME,POSITIVELY IMPACTS
1742,ayahuasca,DRUG,changes in mood and thinking,OUTCOME,POSITIVELY IMPACTS
1743,ayahuasca,DRUG,affect and cognition,OUTCOME,POSITIVELY IMPACTS
1748,ayahuasca,DRUG,affect,SUBJECTIVE,POSITIVELY IMPACTS
1816,hallucinogens,DRUG,alcohol,DRUG,POSITIVELY IMPACTS
1817,psilocybin,DRUG,alcohol,DRUG,POSITIVELY IMPACTS
1818,DMT,DRUG,alcohol,DRUG,POSITIVELY IMPACTS
1821,biochemical reactions,OUTCOME,psychotic state,OUTCOME,POSITIVELY IMPACTS
1822,hallucinogens,DRUG,psychotic state,OUTCOME,POSITIVELY IMPACTS
1824,ayahuasca,DRUG,psychotic state,OUTCOME,POSITIVELY IMPACTS
1825,serotonergic hallucinogens,DRUG,amygdala,NEURAL,POSITIVELY IMPACTS
1826,ayahuasca,DRUG,amygdala,NEURAL,POSITIVELY IMPACTS
1830,psilocybin,DRUG,medial prefrontal cortex,NEURAL,POSITIVELY IMPACTS
1831,psilocybin,DRUG,lingual gyrus,NEURAL,POSITIVELY IMPACTS
1832,psilocybin,DRUG,attenuated right amygdala activation,OUTCOME,POSITIVELY IMPACTS
1833,psilocybin,DRUG,increases in positive mood,OUTCOME,POSITIVELY IMPACTS
1834,psilocybin,DRUG,decreased the threat-induced modulation of top-down connectivity,OUTCOME,POSITIVELY IMPACTS
1835,psilocybin,DRUG,increased parahippocampal cortex/visual cortex functional connectivity,OUTCOME,POSITIVELY IMPACTS
1836,psilocybin,DRUG,parahippocampal cortex to visual cortex information flow,OUTCOME,POSITIVELY IMPACTS
1837,precuneus,NEURAL,self-transcendence”/spirituality,OUTCOME,POSITIVELY IMPACTS
1842,superior frontal gyrus,NEURAL,self-transcendence”/spirituality,OUTCOME,POSITIVELY IMPACTS
1855,increased psychopathology,OUTCOME,self-transcendence”/spirituality,OUTCOME,POSITIVELY IMPACTS
1859,ayahuasca,DRUG,self-transcendence”/spirituality,OUTCOME,POSITIVELY IMPACTS
1860,hallucinogens,DRUG,self-transcendence”/spirituality,OUTCOME,POSITIVELY IMPACTS
1861,serotonergic hallucinogens,DRUG,self-transcendence”/spirituality,OUTCOME,POSITIVELY IMPACTS
1862,serotonergic hallucinogens,DRUG,neocortex,NEURAL,POSITIVELY IMPACTS
1863,serotonergic hallucinogens,DRUG,"genetic, neurochemical, and behavioral alterations",OUTCOME,POSITIVELY IMPACTS
1864,serotonergic hallucinogens,DRUG,brain regions,NEURAL,POSITIVELY IMPACTS
1866,serotonergic hallucinogens,DRUG,γ-aminobutyric acid,DRUG,POSITIVELY IMPACTS
1867,ayahuasca,DRUG,"genetic, neurochemical, and behavioral alterations",OUTCOME,POSITIVELY IMPACTS
1869,ayahuasca,DRUG,γ-aminobutyric acid,DRUG,POSITIVELY IMPACTS
1872,ayahuasca,DRUG,interfered with emotional memory,OUTCOME,POSITIVELY IMPACTS
1873,ayahuasca,DRUG,patterns of neuronal activation,OUTCOME,POSITIVELY IMPACTS
1874,ayahuasca,DRUG,higher neuronal activation,OUTCOME,POSITIVELY IMPACTS
1876,DMN,NEURAL,decrease the power of lower frequency oscillations,OUTCOME,POSITIVELY IMPACTS
1877,serotonergic hallucinogens,DRUG,decrease the power of lower frequency oscillations,OUTCOME,POSITIVELY IMPACTS
1878,serotonergic hallucinogens,DRUG,alpha oscillations,NEURAL,POSITIVELY IMPACTS
1880,parahippocampal region,NEURAL,decrease the power of lower frequency oscillations,OUTCOME,POSITIVELY IMPACTS
1881,altered information flow,OUTCOME,expanded awareness,OUTCOME,POSITIVELY IMPACTS
1882,altered information flow,OUTCOME,unconstrained cognition,OUTCOME,POSITIVELY IMPACTS
1884,compounds,DRUG,antidepressive,OUTCOME,POSITIVELY IMPACTS
1885,compounds,DRUG,anxiolytic,OUTCOME,POSITIVELY IMPACTS
1886,compounds,DRUG,antiaddictive,OUTCOME,POSITIVELY IMPACTS
1887,ayahuasca,DRUG,antidepressive,OUTCOME,POSITIVELY IMPACTS
1893,LSD,DRUG,antidepressive,OUTCOME,POSITIVELY IMPACTS
1896,ayahuasca,DRUG,increases in positive mood,OUTCOME,POSITIVELY IMPACTS
1899,ayahuasca,DRUG,therapeutic potentials,OUTCOME,POSITIVELY IMPACTS
1900,ayahuasca,DRUG,self-transcendence,SUBJECTIVE,POSITIVELY IMPACTS
1902,serotonergic hallucinogens,DRUG,self-transcendence,SUBJECTIVE,POSITIVELY IMPACTS
1903,serotonergic hallucinogens,DRUG,Self-transcendence,SUBJECTIVE,POSITIVELY IMPACTS
1906,religious/mystical experiences,OUTCOME,self-transcendence,SUBJECTIVE,POSITIVELY IMPACTS
1907,psilocybin,DRUG,attitudes,SUBJECTIVE,POSITIVELY IMPACTS
1909,psilocybin,DRUG,alcohol (,OUTCOME,POSITIVELY IMPACTS
1910,religious-like experiences,OUTCOME,mood,SUBJECTIVE,POSITIVELY IMPACTS
1914,LSD,DRUG,attitudes,SUBJECTIVE,POSITIVELY IMPACTS
1918,serotonergic hallucinogens,DRUG,meditation,OUTCOME,POSITIVELY IMPACTS
1919,serotonergic hallucinogens,DRUG,prefrontal and limbic areas,NEURAL,POSITIVELY IMPACTS
1921,compounds,DRUG,meditation,OUTCOME,POSITIVELY IMPACTS
1922,compounds,DRUG,prefrontal and limbic areas,NEURAL,POSITIVELY IMPACTS
1923,compounds,DRUG,decreases in reactivity of brain structures,OUTCOME,POSITIVELY IMPACTS
1925,compounds,DRUG,reduced brain activity in key regions of the DMN,OUTCOME,POSITIVELY IMPACTS
1926,amygdala,NEURAL,prefrontal and limbic areas,NEURAL,POSITIVELY IMPACTS
1927,amygdala,NEURAL,anxiety,HEALTH,POSITIVELY IMPACTS
1928,amygdala,NEURAL,mood disorders,HEALTH,POSITIVELY IMPACTS
1929,amygdala,NEURAL,cortical thickness alterations,OUTCOME,POSITIVELY IMPACTS
1935,serotonergic hallucinogens,DRUG,mood disorders,HEALTH,POSITIVELY IMPACTS
1936,serotonergic hallucinogens,DRUG,cortical thickness alterations,OUTCOME,POSITIVELY IMPACTS
1937,drugs,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
1939,drugs,DRUG,mood disorders,HEALTH,POSITIVELY IMPACTS
1940,drugs,DRUG,cortical thickness alterations,OUTCOME,POSITIVELY IMPACTS
1941,DMN,NEURAL,mood disorders,HEALTH,POSITIVELY IMPACTS
1942,posterior,NEURAL,anxiety,HEALTH,POSITIVELY IMPACTS
1943,posterior,NEURAL,mood disorders,HEALTH,POSITIVELY IMPACTS
1944,serotonergic hallucinogens,DRUG,psychiatric disorders,HEALTH,POSITIVELY IMPACTS
1945,serotonergic hallucinogens,DRUG,therapeutic uses,OUTCOME,POSITIVELY IMPACTS
1946,serotonergic hallucinogens,DRUG,treatment-resistant patients,HEALTH,POSITIVELY IMPACTS
1951,psilocybin,DRUG,"deeply meaningful, mystical experiences",OUTCOME,POSITIVELY IMPACTS
1953,Indocybin,DRUG,mood disorder,HEALTH,POSITIVELY IMPACTS
1954,psychedelic drugs,DRUG,toxicity ratio,OUTCOME,POSITIVELY IMPACTS
1955,psychedelic drugs,DRUG,fluoxetine,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
1956,psilocybin,DRUG,toxicity ratio,OUTCOME,POSITIVELY IMPACTS
1957,psilocybin,DRUG,fluoxetine,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
1958,LSD,DRUG,brain damage,OUTCOME,POSITIVELY IMPACTS
1960,LSD,DRUG,long-lasting personality change,OUTCOME,POSITIVELY IMPACTS
1971,psychedelic drugs,DRUG,brain damage,OUTCOME,POSITIVELY IMPACTS
1972,psychedelic drugs,DRUG,long-lasting personality change,OUTCOME,POSITIVELY IMPACTS
1975,serotonergic psychedelics,DRUG,opiate overdoses(National,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
1976,psilocybin,DRUG,opiate overdoses(National,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
1977,escitalopram,ANTIDEPRESSANT_DRUG,depression,HEALTH,POSITIVELY IMPACTS
1987,psilocybin,DRUG,mediating influence on positive outcomes.21,OUTCOME,POSITIVELY IMPACTS
1988,psilocybin,DRUG,psychiatric conditions,HEALTH,POSITIVELY IMPACTS
1991,psychological support,OUTCOME,improved outcomes,OUTCOME,POSITIVELY IMPACTS
1992,psychological support,OUTCOME,subjective effects,SUBJECTIVE,POSITIVELY IMPACTS
1994,psilocybin,DRUG,improved outcomes,OUTCOME,POSITIVELY IMPACTS
1998,Psychedelic agents,DRUG,depression,HEALTH,POSITIVELY IMPACTS
2000,Psychedelic agents,DRUG,treatment-resistant depression,HEALTH,POSITIVELY IMPACTS
2001,Psychedelic agents,DRUG,"enhance suggestibility,23",OUTCOME,POSITIVELY IMPACTS
2003,Psychedelic agents,DRUG,increase dendritic arbor complexity,OUTCOME,POSITIVELY IMPACTS
2009,psychological effects,OUTCOME,neuronal plasticity,OUTCOME,POSITIVELY IMPACTS
2013,psychedelic compounds,DRUG,depression,HEALTH,POSITIVELY IMPACTS
2014,psychedelic compounds,DRUG,increase dendritic arbor complexity,OUTCOME,POSITIVELY IMPACTS
2015,psychedelic compounds,DRUG,neuronal plasticity,OUTCOME,POSITIVELY IMPACTS
2016,compounds,DRUG,neuronal plasticity,OUTCOME,POSITIVELY IMPACTS
2019,5-HT2A receptor,NEURAL,neuronal plasticity,OUTCOME,POSITIVELY IMPACTS
2020,psychedelics,DRUG,neuronal plasticity,OUTCOME,POSITIVELY IMPACTS
2021,escitalopram,ANTIDEPRESSANT_DRUG,neuronal plasticity,OUTCOME,POSITIVELY IMPACTS
2022,psilocybin,DRUG,increase dendritic arbor complexity,OUTCOME,POSITIVELY IMPACTS
2023,psilocybin,DRUG,neuronal plasticity,OUTCOME,POSITIVELY IMPACTS
2026,escitalopram,ANTIDEPRESSANT_DRUG,increase dendritic arbor complexity,OUTCOME,POSITIVELY IMPACTS
2028,psilocybin,DRUG,microdoses,DRUG,POSITIVELY IMPACTS
2029,psilocybin,DRUG,microdosed,DRUG,POSITIVELY IMPACTS
2030,psilocybin,DRUG,mood and cognitive enhancers,OUTCOME,POSITIVELY IMPACTS
2031,psychedelic microdosing,DRUG,depression,HEALTH,POSITIVELY IMPACTS
2032,performance improvements,OUTCOME,anxiety,HEALTH,POSITIVELY IMPACTS
2034,OCD,HEALTH,anxiety,HEALTH,POSITIVELY IMPACTS
2037,LSD,DRUG,functional drug use,OUTCOME,POSITIVELY IMPACTS
2038,psychedelic drugs,DRUG,functional drug use,OUTCOME,POSITIVELY IMPACTS
2039,Psychedelics,DRUG,functional drug use,OUTCOME,POSITIVELY IMPACTS
2040,Psychedelics,DRUG,avoiding the problems,OUTCOME,POSITIVELY IMPACTS
2041,microdosing,DRUG,less constructive and self-reflective approach,OUTCOME,POSITIVELY IMPACTS
2042,psychedelics,DRUG,improved disease coping strategies and attitudes,OUTCOME,POSITIVELY IMPACTS
2043,LSD,DRUG,self-reflection,SUBJECTIVE,POSITIVELY IMPACTS
2044,DMN,NEURAL,self-reflection,SUBJECTIVE,POSITIVELY IMPACTS
2045,DMN,NEURAL,spontaneous cognition,SUBJECTIVE,POSITIVELY IMPACTS
2046,DMN,NEURAL,cognition,SUBJECTIVE,POSITIVELY IMPACTS
2052,psilocybin,DRUG,autobiographical memory,OUTCOME,POSITIVELY IMPACTS
2053,psilocybin,DRUG,preservation of the sense of self,OUTCOME,POSITIVELY IMPACTS
2054,psilocybin,DRUG,maintenance of one’s sense of self,OUTCOME,POSITIVELY IMPACTS
2055,LSD,DRUG,maintenance of one’s sense of self,OUTCOME,POSITIVELY IMPACTS
2056,psychedelic,DRUG,maintenance of one’s sense of self,OUTCOME,POSITIVELY IMPACTS
2057,psychedelic,DRUG,self-loss,SUBJECTIVE,POSITIVELY IMPACTS
2058,autobiographical information,OUTCOME,secure sense of self,OUTCOME,POSITIVELY IMPACTS
2059,LSD,DRUG,autobiographical memory,SUBJECTIVE,POSITIVELY IMPACTS
2060,LSD,DRUG,self,SUBJECTIVE,POSITIVELY IMPACTS
2061,psychedelic,DRUG,highly salient and/or traumatic events,OUTCOME,POSITIVELY IMPACTS
2062,altered) states of consciousness,SUBJECTIVE,spontaneous cognition,OUTCOME,POSITIVELY IMPACTS
2067,LSD,DRUG,intoxicant,DRUG,POSITIVELY IMPACTS
2068,LSD,DRUG,mentation about the future,OUTCOME,POSITIVELY IMPACTS
2069,LSD,DRUG,alcohol,DRUG,POSITIVELY IMPACTS
2071,exhilarating,DRUG,alcohol,DRUG,POSITIVELY IMPACTS
2072,exhilarating,DRUG,past-focused mentation,SUBJECTIVE,POSITIVELY IMPACTS
2073,exhilarating,DRUG,past-focused reflection,SUBJECTIVE,POSITIVELY IMPACTS
2074,exhilarating experiences,HEALTH,alcohol,DRUG,POSITIVELY IMPACTS
2075,exhilarating experiences,HEALTH,past-focused reflection,SUBJECTIVE,POSITIVELY IMPACTS
2078,psychedelics,DRUG,alcohol,DRUG,POSITIVELY IMPACTS
2080,psilocybin,DRUG,past-focused reflection,SUBJECTIVE,POSITIVELY IMPACTS
2082,psychedelics,DRUG,promoting a mental state,OUTCOME,POSITIVELY IMPACTS
2083,psychedelics,DRUG,mindfulness-promoting effects,OUTCOME,POSITIVELY IMPACTS
2084,LSD,DRUG,promoting a mental state,OUTCOME,POSITIVELY IMPACTS
2085,LSD,DRUG,mindfulness-promoting effects,OUTCOME,POSITIVELY IMPACTS
2087,psychedelic compounds,DRUG,sustained changes in attitudes and beliefs,OUTCOME,POSITIVELY IMPACTS
2088,psychedelic compounds,DRUG,trait openness,OUTCOME,POSITIVELY IMPACTS
2089,psychedelic compounds,DRUG,optimism,OUTCOME,POSITIVELY IMPACTS
2091,psilocybin,DRUG,reduction of depressive symptoms,OUTCOME,POSITIVELY IMPACTS
2093,psilocybin,DRUG,optimism,OUTCOME,POSITIVELY IMPACTS
2094,psilocybin,DRUG,enduring reductions in anxiety,OUTCOME,POSITIVELY IMPACTS
2096,psilocybin,DRUG,"life meaning, and optimism",OUTCOME,POSITIVELY IMPACTS
2099,psilocybin,DRUG,rapid and sustained antidepressant effects,OUTCOME,POSITIVELY IMPACTS
2100,psilocybin,DRUG,MDD,HEALTH,POSITIVELY IMPACTS
2102,greater nature relatedness,OUTCOME,depression,HEALTH,POSITIVELY IMPACTS
2103,psychedelic,DRUG,nature-inspiring experiences of awe,OUTCOME,POSITIVELY IMPACTS
2104,psychedelic,DRUG,cognitive and affective benefits,OUTCOME,POSITIVELY IMPACTS
2106,psilocybin,DRUG,sense of ‘connectedness,SUBJECTIVE,POSITIVELY IMPACTS
2107,Psychedelic drug,DRUG,higher on attitudes of,OUTCOME,POSITIVELY IMPACTS
2108,psychedelic,DRUG,higher on attitudes of,OUTCOME,POSITIVELY IMPACTS
2109,psychedelics,DRUG,higher on attitudes of,OUTCOME,POSITIVELY IMPACTS
2110,psychedelics,DRUG,lower value on ‘financial prosperity,OUTCOME,POSITIVELY IMPACTS
2112,psychedelics,DRUG,increase trait openness,OUTCOME,POSITIVELY IMPACTS
2113,psychedelics,DRUG,positive association between openness and liberalism,OUTCOME,POSITIVELY IMPACTS
2114,selective serotonin reuptake inhibitors,ANTIDEPRESSANT_DRUG,alcohol,DRUG,POSITIVELY IMPACTS
2115,selective serotonin reuptake inhibitors,ANTIDEPRESSANT_DRUG,profound implications,OUTCOME,POSITIVELY IMPACTS
2116,selective serotonin reuptake inhibitors,ANTIDEPRESSANT_DRUG,promote a generalised sense of connectedness,OUTCOME,POSITIVELY IMPACTS
2117,psychedelic,DRUG,profound implications,OUTCOME,POSITIVELY IMPACTS
2118,psychedelic,DRUG,promote a generalised sense of connectedness,OUTCOME,POSITIVELY IMPACTS
2119,psilocybin,DRUG,authoritarian attitudes,OUTCOME,POSITIVELY IMPACTS
2121,AYA,DRUG,antiaddictive,OUTCOME,POSITIVELY IMPACTS
2123,psychedelic substances,DRUG,antiaddictive,OUTCOME,POSITIVELY IMPACTS
2125,AYA,DRUG,antidepressive,OUTCOME,POSITIVELY IMPACTS
2128,AYA,DRUG,sense of “self,SUBJECTIVE,POSITIVELY IMPACTS
2130,hallucinogens,DRUG,antidepressive,OUTCOME,POSITIVELY IMPACTS
2133,psilocybin,DRUG,reduced amygdala reactivity,OUTCOME,POSITIVELY IMPACTS
2136,AYA,DRUG,brain,NEURAL,POSITIVELY IMPACTS
2137,AYA,DRUG,attentional processes,OUTCOME,POSITIVELY IMPACTS
2146,hypomania,OUTCOME,bipolar disorders,HEALTH,POSITIVELY IMPACTS
2148,optimism,OUTCOME,life attitudes and views,OUTCOME,POSITIVELY IMPACTS
2149,AYA,DRUG,changes in personality traits,OUTCOME,POSITIVELY IMPACTS
2150,AYA,DRUG,life attitudes and views,OUTCOME,POSITIVELY IMPACTS
2151,AYA,DRUG,shyness,OUTCOME,POSITIVELY IMPACTS
2152,AYA,DRUG,transpersonal feelings and spirituality,OUTCOME,POSITIVELY IMPACTS
2154,AYA,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
2155,psilocybin,DRUG,modulated effective connectivity,OUTCOME,POSITIVELY IMPACTS
2156,psilocybin,DRUG,threat-processing,OUTCOME,POSITIVELY IMPACTS
2157,AMG,NEURAL,visual threat processing,NEURAL,POSITIVELY IMPACTS
2159,psilocybin,DRUG,attenuation of top-down threat signaling,OUTCOME,POSITIVELY IMPACTS
2160,psilocybin,DRUG,decreased threat sensitivity in the visual cortex,OUTCOME,POSITIVELY IMPACTS
2163,psilocybin,DRUG,attenuation of top-down connectivity,OUTCOME,POSITIVELY IMPACTS
2166,psilocybin,DRUG,decrease of behavioral and electrophysiological responses in the visual cortex to threat stimuli,OUTCOME,POSITIVELY IMPACTS
2168,psilocybin,DRUG,threat processing,OUTCOME,POSITIVELY IMPACTS
2170,psilocybin,DRUG,visual cortex,NEURAL,POSITIVELY IMPACTS
2176,psilocybin,DRUG,inhibitory top-down connectivity,OUTCOME,POSITIVELY IMPACTS
2177,psilocybin,DRUG,increased LPFC → AMG top-down connectivity,OUTCOME,POSITIVELY IMPACTS
2178,psilocybin,DRUG,increase top-down connectivity,OUTCOME,POSITIVELY IMPACTS
2179,psilocybin,DRUG,reduction of AMG activity,OUTCOME,POSITIVELY IMPACTS
2180,psilocybin,DRUG,increased top-down effect,OUTCOME,POSITIVELY IMPACTS
2186,psilocybin,DRUG,reduced top-down connectivity,OUTCOME,POSITIVELY IMPACTS
2187,psilocybin,DRUG,reduced top-down modulation,OUTCOME,POSITIVELY IMPACTS
2192,psilocybin,DRUG,amygdala neurons,NEURAL,POSITIVELY IMPACTS
2193,DOI,NEURAL,reduced top-down connectivity,OUTCOME,POSITIVELY IMPACTS
2194,DOI,NEURAL,amygdala neurons,NEURAL,POSITIVELY IMPACTS
2195,AMG,NEURAL,reduced top-down connectivity,OUTCOME,POSITIVELY IMPACTS
2196,AMG,NEURAL,reduced top-down modulation,OUTCOME,POSITIVELY IMPACTS
2197,AMG,NEURAL,amygdala neurons,NEURAL,POSITIVELY IMPACTS
2198,selective serotonin reuptake inhibitor,ANTIDEPRESSANT_DRUG,amygdala,NEURAL,POSITIVELY IMPACTS
2200,psychedelic,DRUG,emotional breakthrough,OUTCOME,POSITIVELY IMPACTS
2201,EBI,NEURAL,emotional breakthrough,OUTCOME,POSITIVELY IMPACTS
2202,psychedelic,DRUG,therapeutic setting,OUTCOME,POSITIVELY IMPACTS
2204,psychedelic,DRUG,state,SUBJECTIVE,POSITIVELY IMPACTS
2207,psychedelic,DRUG,increased brain entropy,OUTCOME,POSITIVELY IMPACTS
2209,psychedelic,DRUG,increased trait ‘openness,OUTCOME,POSITIVELY IMPACTS
2212,Psychedelics,DRUG,depressive symptoms,HEALTH,POSITIVELY IMPACTS
2213,DMT,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
2215,DMT,DRUG,shorter total distance,OUTCOME,POSITIVELY IMPACTS
2218,DMT,DRUG,spatial memory,OUTCOME,POSITIVELY IMPACTS
2219,decreased rearing,OUTCOME,anxiety,HEALTH,POSITIVELY IMPACTS
2222,compounds,DRUG,lasting impact on fear memory,OUTCOME,POSITIVELY IMPACTS
2223,DMT,DRUG,stronger extinction memory,OUTCOME,POSITIVELY IMPACTS
2224,DMT,DRUG,increases swimming behavior,OUTCOME,POSITIVELY IMPACTS
2225,selective serotonin reuptake inhibitors,ANTIDEPRESSANT_DRUG,fluoxetine,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
2226,ayahuasca,DRUG,fluoxetine,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
2228,ayahuasca,DRUG,treatment-resistant populations,HEALTH,POSITIVELY IMPACTS
2229,ketamine,DRUG,fluoxetine,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
2230,ketamine,DRUG,long-lasting,OUTCOME,POSITIVELY IMPACTS
2233,ketamine,DRUG,treatment-resistant populations,HEALTH,POSITIVELY IMPACTS
2235,ketamine,DRUG,brain,NEURAL,POSITIVELY IMPACTS
2238,ketamine,DRUG,long-lasting changes,OUTCOME,POSITIVELY IMPACTS
2239,DMT,DRUG,long-lasting changes,OUTCOME,POSITIVELY IMPACTS
2240,NMDA,NEURAL,long-lasting changes,OUTCOME,POSITIVELY IMPACTS
2243,ayahausca,DRUG,long-lasting changes,OUTCOME,POSITIVELY IMPACTS
2244,ayahausca,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
2245,DMT,DRUG,depression,HEALTH,POSITIVELY IMPACTS
2256,serotonergic psychedelic,DRUG,depression,HEALTH,POSITIVELY IMPACTS
2262,DMT,DRUG,antidepressants,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
2270,ayahuasca,DRUG,antidepressants,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
2271,serotonergic psychedelics,DRUG,depression,HEALTH,POSITIVELY IMPACTS
2275,LSD,DRUG,behavior,SUBJECTIVE,POSITIVELY IMPACTS
2276,LSD,DRUG,detectable subjective effects,OUTCOME,POSITIVELY IMPACTS
2277,LSD,DRUG,increases in ratings of drug effects scales,OUTCOME,POSITIVELY IMPACTS
2278,LSD,DRUG,subjective and behavioral effects,OUTCOME,POSITIVELY IMPACTS
2279,LSD,DRUG,microdoses,DRUG,POSITIVELY IMPACTS
2287,LSD,DRUG,feel drug,OUTCOME,POSITIVELY IMPACTS
2288,LSD,DRUG,drug,OUTCOME,POSITIVELY IMPACTS
2294,LSD,DRUG,effects on mood,OUTCOME,POSITIVELY IMPACTS
2296,LSD,DRUG,mood disturbances,HEALTH,POSITIVELY IMPACTS
2297,drug,DRUG,depression,HEALTH,POSITIVELY IMPACTS
2298,drug,DRUG,stress,OUTCOME,POSITIVELY IMPACTS
2299,drug,DRUG,lower distractibility,OUTCOME,POSITIVELY IMPACTS
2304,microdosing psilocybin,DRUG,improved convergent and divergent thinking,OUTCOME,POSITIVELY IMPACTS
2305,psilocybin,DRUG,reduced feelings of social rejection,OUTCOME,POSITIVELY IMPACTS
2308,drugs,DRUG,therapeutic affects,OUTCOME,POSITIVELY IMPACTS
2309,drugs,DRUG,the drug,DRUG,POSITIVELY IMPACTS
2312,drug,DRUG,the drug,DRUG,POSITIVELY IMPACTS
2313,drug,DRUG,improves mood and cognition,OUTCOME,POSITIVELY IMPACTS
2314,drug,DRUG,understanding of the neural and behavioral processes,OUTCOME,POSITIVELY IMPACTS
2315,drug,DRUG,depressed mood,HEALTH,POSITIVELY IMPACTS
2316,psychedelic microdosing,DRUG,lower dysfunctional attitudes and negative emotionality,OUTCOME,POSITIVELY IMPACTS
2317,psychedelic microdosing,DRUG,"higher wisdom, open-mindedness, and creativity",OUTCOME,POSITIVELY IMPACTS
2318,microdosing,DRUG,lower dysfunctional attitudes and negative emotionality,OUTCOME,POSITIVELY IMPACTS
2319,microdosing,DRUG,"higher wisdom, open-mindedness, and creativity",OUTCOME,POSITIVELY IMPACTS
2322,LSD,DRUG,lower dysfunctional attitudes and negative emotionality,OUTCOME,POSITIVELY IMPACTS
2323,LSD,DRUG,"higher wisdom, open-mindedness, and creativity",OUTCOME,POSITIVELY IMPACTS
2324,psilocybin,DRUG,lower dysfunctional attitudes and negative emotionality,OUTCOME,POSITIVELY IMPACTS
2325,psilocybin,DRUG,"higher wisdom, open-mindedness, and creativity",OUTCOME,POSITIVELY IMPACTS
2326,psilocybin,DRUG,meaningfully lower levels of dysfunctional attitudes,OUTCOME,POSITIVELY IMPACTS
2329,microdosing,DRUG,meaningfully lower levels of dysfunctional attitudes,OUTCOME,POSITIVELY IMPACTS
2330,microdosing,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
2331,microdosing,DRUG,depression,HEALTH,POSITIVELY IMPACTS
2332,microdosers,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
2333,microdosers,DRUG,depression,HEALTH,POSITIVELY IMPACTS
2334,microdosers,DRUG,positive emotional valence,OUTCOME,POSITIVELY IMPACTS
2336,microdosers,DRUG,enhanced capacity for perspective taking,OUTCOME,POSITIVELY IMPACTS
2337,microdosers,DRUG,resilience in the face of the vicissitudes of life,OUTCOME,POSITIVELY IMPACTS
2338,microdosers,DRUG,increased feelings of engagement and connection,OUTCOME,POSITIVELY IMPACTS
2339,microdosers,DRUG,increases in openness,OUTCOME,POSITIVELY IMPACTS
2340,microdosing,DRUG,creativity,DRUG,POSITIVELY IMPACTS
2341,microdosing,DRUG,mood,DRUG,POSITIVELY IMPACTS
2346,decreased amygdala responsiveness,OUTCOME,therapeutic action,OUTCOME,POSITIVELY IMPACTS
2347,SSRIs,ANTIDEPRESSANT_DRUG,therapeutic action,OUTCOME,POSITIVELY IMPACTS
2348,psilocybin,DRUG,therapeutic action,OUTCOME,POSITIVELY IMPACTS
2350,psilocybin,DRUG,make emotional ‘confrontation’ more likely,OUTCOME,POSITIVELY IMPACTS
2351,psilocybin,DRUG,emotional breakthrough,OUTCOME,POSITIVELY IMPACTS
2352,psilocybin,DRUG,resolution,OUTCOME,POSITIVELY IMPACTS
2355,psilocybin,DRUG,antidepressant action,OUTCOME,POSITIVELY IMPACTS
2356,psilocybin,DRUG,changes in spontaneous brain function,OUTCOME,POSITIVELY IMPACTS
2357,psilocybin,DRUG,acute brain effects,OUTCOME,POSITIVELY IMPACTS
2364,psilocybin,DRUG,post treatment brain changes,OUTCOME,POSITIVELY IMPACTS
2365,psilocybin,DRUG,functional brain measures,OUTCOME,POSITIVELY IMPACTS
2367,psilocybin,DRUG,novel intervention for major depression,OUTCOME,POSITIVELY IMPACTS
2369,Psilocybin,DRUG,depressed patients,HEALTH,POSITIVELY IMPACTS
2370,Psilocybin,DRUG,novel intervention for major depression,OUTCOME,POSITIVELY IMPACTS
2371,Psilocybin,DRUG,"safe, rapid and potentially enduring in its antidepressant action",OUTCOME,POSITIVELY IMPACTS
2374,cancer-related psychiatric and existential distress,HEALTH,depression,HEALTH,POSITIVELY IMPACTS
2375,psilocybin,DRUG,cancer-related psychiatric and existential distress,HEALTH,POSITIVELY IMPACTS
2378,psilocybin,DRUG,hopelessness,OUTCOME,POSITIVELY IMPACTS
2379,psilocybin,DRUG,demoralization,OUTCOME,POSITIVELY IMPACTS
2380,psilocybin,DRUG,death anxiety,OUTCOME,POSITIVELY IMPACTS
2381,psilocybin,DRUG,spiritual well-being,OUTCOME,POSITIVELY IMPACTS
2386,hopelessness,OUTCOME,depression,HEALTH,POSITIVELY IMPACTS
2388,antidepressant or anxiolytic response,OUTCOME,depression,HEALTH,POSITIVELY IMPACTS
2389,subjective experiences of positive changes,OUTCOME,depression,HEALTH,POSITIVELY IMPACTS
2394,psilocybin,DRUG,subjective experiences of positive changes,OUTCOME,POSITIVELY IMPACTS
2397,psilocybin,DRUG,personally meaningful and spiritually significant experiences,OUTCOME,POSITIVELY IMPACTS
2398,psilocybin,DRUG,existential distress,HEALTH,POSITIVELY IMPACTS
2399,personally meaningful and spiritually significant experiences,OUTCOME,depression,HEALTH,POSITIVELY IMPACTS
2405,psilocybin,DRUG,cancer-related existential distress,HEALTH,POSITIVELY IMPACTS
2412,psilocybin,DRUG,promising protective strategy against suicides,OUTCOME,POSITIVELY IMPACTS
2413,psilocybin,DRUG,passive suicidality,HEALTH,POSITIVELY IMPACTS
2418,psilocybin,DRUG,cancer-related distress,HEALTH,POSITIVELY IMPACTS
2420,psilocybin,DRUG,stronger reductions in subjective reports of depression,OUTCOME,POSITIVELY IMPACTS
2423,psilocybin,DRUG,anxiolytic and antidepressant effects,OUTCOME,POSITIVELY IMPACTS
2424,mystical-type experience,SUBJECTIVE,anxiolytic and antidepressant effects,OUTCOME,POSITIVELY IMPACTS
2427,psilocybin,DRUG,addictive disorders,HEALTH,POSITIVELY IMPACTS
2428,psilocybin,DRUG,increases in trait openness,OUTCOME,POSITIVELY IMPACTS
2430,Psychedelic-induced states of consciousness,SUBJECTIVE,increases in trait openness,OUTCOME,POSITIVELY IMPACTS
2431,Psychedelic-induced states of consciousness,SUBJECTIVE,cognitive flexibility,OUTCOME,POSITIVELY IMPACTS
2432,Psychedelic-induced states of consciousness,SUBJECTIVE,treatment-resistant depression,HEALTH,POSITIVELY IMPACTS
2433,psilocybin,DRUG,dissolution of boundaries,SUBJECTIVE,POSITIVELY IMPACTS
2434,psilocybin,DRUG,feelings of unity,SUBJECTIVE,POSITIVELY IMPACTS
2436,psilocybin,DRUG,cope with life stressors,OUTCOME,POSITIVELY IMPACTS
2444,psilocybin,DRUG,emotional processing,OUTCOME,POSITIVELY IMPACTS
2445,psilocybin,DRUG,emotional regulation in the long-term,OUTCOME,POSITIVELY IMPACTS
2454,psilocybin,DRUG,"highly memorable, meaningful, and spiritually significant effects",OUTCOME,POSITIVELY IMPACTS
2455,psilocybin,DRUG,inherently confer therapeutic benefits,OUTCOME,POSITIVELY IMPACTS
2471,psychedelic compounds,DRUG,antidepressants,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
2472,psychedelic compounds,DRUG,monoaminergic enhancement,NEURAL,POSITIVELY IMPACTS
2474,psychedelics,DRUG,antidepressants,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
2475,psychedelics,DRUG,monoaminergic enhancement,NEURAL,POSITIVELY IMPACTS
2479,PLA,DRUG,rapid action,OUTCOME,POSITIVELY IMPACTS
2481,BDNF,NEURAL,BDNF,SUBJECTIVE,POSITIVELY IMPACTS
2483,ayahuasca,DRUG,lower symptoms of depression,OUTCOME,POSITIVELY IMPACTS
2484,ayahuasca,DRUG,antidepressant,ANTIDEPRESSANT_DRUG,POSITIVELY IMPACTS
2485,psilocybin,DRUG,cancer-related emotional distress,HEALTH,POSITIVELY IMPACTS
2486,psilocybin,DRUG,"rapid, substantial, and enduring anxiolytic and antidepressant effects",OUTCOME,POSITIVELY IMPACTS
2487,psilocybin,DRUG,cancer-related psychological and existential distress,HEALTH,POSITIVELY IMPACTS
2489,psilocybin,DRUG,symptoms of distress,OUTCOME,POSITIVELY IMPACTS
2492,Chrissy,DRUG,death,HEALTH,POSITIVELY IMPACTS
2494,cord to the universe,SUBJECTIVE,death,HEALTH,POSITIVELY IMPACTS
2497,mystical-type experiences,SUBJECTIVE,death,HEALTH,POSITIVELY IMPACTS
2500,cancer,HEALTH,death,HEALTH,POSITIVELY IMPACTS
2502,death,HEALTH,death,HEALTH,POSITIVELY IMPACTS
2503,no longer being preoccupied or overwhelmed by fear,OUTCOME,death,HEALTH,POSITIVELY IMPACTS
2504,psilocybin,DRUG,release of complicated emotions,OUTCOME,POSITIVELY IMPACTS
2509,psilocybin,DRUG,expanded perspective on,OUTCOME,POSITIVELY IMPACTS
2510,psilocybin,DRUG,Transcendence,SUBJECTIVE,POSITIVELY IMPACTS
2511,psilocybin,DRUG,greater meaning to suffering,OUTCOME,POSITIVELY IMPACTS
2512,psilocybin,DRUG,spiritually significant,OUTCOME,POSITIVELY IMPACTS
2513,psilocybin,DRUG,personally meaningful experiences,OUTCOME,POSITIVELY IMPACTS
2514,psilocybin,DRUG,spiritual significance,OUTCOME,POSITIVELY IMPACTS
2515,psilocybin,DRUG,expanded life priorities,OUTCOME,POSITIVELY IMPACTS
2519,psilocybin,DRUG,emotions,SUBJECTIVE,POSITIVELY IMPACTS
2520,psilocybin,DRUG,positive attributes in meaning,OUTCOME,POSITIVELY IMPACTS
2525,psilocybin,DRUG,heightened sense of meaning and perspective,OUTCOME,POSITIVELY IMPACTS
2526,psilocybin,DRUG,positive changes in individuals lives,OUTCOME,POSITIVELY IMPACTS
2527,psilocybin,DRUG,increase in well-being,OUTCOME,POSITIVELY IMPACTS
2528,psilocybin,DRUG,sense of life priority,OUTCOME,POSITIVELY IMPACTS
2532,enduring effects,OUTCOME,cancer,HEALTH,POSITIVELY IMPACTS
2534,death,HEALTH,cancer,HEALTH,POSITIVELY IMPACTS
2540,DLPFC,NEURAL,enhanced amygdala recruitment,OUTCOME,POSITIVELY IMPACTS
2543,RSNs,NEURAL,thalamus,NEURAL,POSITIVELY IMPACTS
2544,LSD,DRUG,thalamus,NEURAL,POSITIVELY IMPACTS
2545,psilocybin,DRUG,thalamus,NEURAL,POSITIVELY IMPACTS
2564,hallucinogenic drugs,DRUG,striatum,NEURAL,POSITIVELY IMPACTS
2566,altered hub connectivity,NEURAL,depression,HEALTH,POSITIVELY IMPACTS
2567,altered hub connectivity,NEURAL,anxiety,HEALTH,POSITIVELY IMPACTS
2568,altered hub connectivity,NEURAL,addiction,HEALTH,POSITIVELY IMPACTS
2570,hallucinogens,DRUG,depression,HEALTH,POSITIVELY IMPACTS
2571,hallucinogens,DRUG,addiction,HEALTH,POSITIVELY IMPACTS
2576,LSD,DRUG,neurovascular coupling,NEURAL,POSITIVELY IMPACTS
2577,LSD,DRUG,negatively influenced subjective drug effects,OUTCOME,POSITIVELY IMPACTS
2578,psychedelics,DRUG,emotion,SUBJECTIVE,POSITIVELY IMPACTS
2579,psychedelics,DRUG,self-regulation,SUBJECTIVE,POSITIVELY IMPACTS
2580,psychedelics,DRUG,trans-diagnostic treatment mechanisms in psychiatry,OUTCOME,POSITIVELY IMPACTS
2581,psychedelics,DRUG,development of novel rapid-acting and long-lasting treatment approaches,OUTCOME,POSITIVELY IMPACTS
2583,psychedelics,DRUG,regulation,SUBJECTIVE,POSITIVELY IMPACTS
2591,DMN,NEURAL,signal complexity,OUTCOME,POSITIVELY IMPACTS
2592,LSD,DRUG,signal complexity,OUTCOME,POSITIVELY IMPACTS
2593,psilocybin,DRUG,functional and directed connectivity,NEURAL,POSITIVELY IMPACTS
2594,psilocybin,DRUG,increased synchrony of sensory brain regions,NEURAL,POSITIVELY IMPACTS
2595,psilocybin,DRUG,decreased integrity of associative brain regions,NEURAL,POSITIVELY IMPACTS
2596,psilocybin,DRUG,entropy,OUTCOME,POSITIVELY IMPACTS
2597,psilocybin,DRUG,signal complexity,OUTCOME,POSITIVELY IMPACTS
2598,psilocybin,DRUG,neuronal dynamics,NEURAL,POSITIVELY IMPACTS
2603,psychedelics,DRUG,neuronal dynamics,NEURAL,POSITIVELY IMPACTS
2604,psychedelics,DRUG,modulate a person’s self-focus,OUTCOME,POSITIVELY IMPACTS
2605,psychedelics,DRUG,reduce negative emotional processing,OUTCOME,POSITIVELY IMPACTS
2606,psychedelics,DRUG,strengthen social,OUTCOME,POSITIVELY IMPACTS
2607,psychedelics,DRUG,trans-diagnostic mechanisms,OUTCOME,POSITIVELY IMPACTS
2608,psychedelics,DRUG,long-lasting effects,OUTCOME,POSITIVELY IMPACTS
2609,psychedelic,DRUG,"molecular, systems-level and functional alterations",OUTCOME,POSITIVELY IMPACTS
2610,psychedelics,DRUG,"molecular, systems-level and functional alterations",OUTCOME,POSITIVELY IMPACTS
2611,psychedelic substances,DRUG,"molecular, systems-level and functional alterations",OUTCOME,POSITIVELY IMPACTS
2612,psilocybin,DRUG,neuromodulator systems,DRUG,POSITIVELY IMPACTS
2613,psilocybin,DRUG,brain,NEURAL,POSITIVELY IMPACTS
2614,serotonin system,NEURAL,brain,NEURAL,POSITIVELY IMPACTS
2616,psilocybin,DRUG,multilevel plasticity,OUTCOME,POSITIVELY IMPACTS
2620,selective serotonin reuptake inhibitors,ANTIDEPRESSANT_DRUG,multilevel plasticity,OUTCOME,POSITIVELY IMPACTS
2621,selective serotonin reuptake inhibitors,ANTIDEPRESSANT_DRUG,therapeutic action,OUTCOME,POSITIVELY IMPACTS
2622,selective serotonin reuptake inhibitors,ANTIDEPRESSANT_DRUG,treatment-resistant depression,HEALTH,POSITIVELY IMPACTS
2647,Ayahuasca,DRUG,depression,HEALTH,POSITIVELY IMPACTS
2648,Ayahuasca,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
2663,psychedelic,DRUG,mood,OUTCOME,POSITIVELY IMPACTS
2664,psychedelic,DRUG,reduced feelings of apprehension,OUTCOME,POSITIVELY IMPACTS
2666,psychedelic,DRUG,anti-depressant and anxiolytic effects,OUTCOME,POSITIVELY IMPACTS
2667,psychedelic,DRUG,spiritually meaningful,OUTCOME,POSITIVELY IMPACTS
2668,psychedelic,DRUG,decreased disease-related demoralisation,OUTCOME,POSITIVELY IMPACTS
2669,psychedelic,DRUG,hopelessness,OUTCOME,POSITIVELY IMPACTS
2670,psychedelic,DRUG,improved quality of life,OUTCOME,POSITIVELY IMPACTS
2673,psychedelics,DRUG,self-resolving,OUTCOME,POSITIVELY IMPACTS
2678,serotonin (5-HT2A) receptor downregulation,NEURAL,suicidality,OUTCOME,POSITIVELY IMPACTS
2679,psychedelic users,HEALTH,lower rates of psychological distress,OUTCOME,POSITIVELY IMPACTS
2680,psychedelic users,HEALTH,suicidality,OUTCOME,POSITIVELY IMPACTS
2681,psychedelics,DRUG,suicidality,OUTCOME,POSITIVELY IMPACTS
2682,psychedelics,DRUG,lower rates of psychological distress,OUTCOME,POSITIVELY IMPACTS
2684,psychedelics,DRUG,heightened state of consciousness,SUBJECTIVE,POSITIVELY IMPACTS
2685,psychedelic,DRUG,heightened state of consciousness,SUBJECTIVE,POSITIVELY IMPACTS
2694,expectancy,OUTCOME,somatic diseases,HEALTH,POSITIVELY IMPACTS
2696,psilocybin,DRUG,psychoactive effects,OUTCOME,POSITIVELY IMPACTS
2700,psychedelics,DRUG,comparable anti-depressant and anxiolytic effects,OUTCOME,POSITIVELY IMPACTS
2701,Ayahuasca,DRUG,entropy increases,OUTCOME,POSITIVELY IMPACTS
2702,Ayahuasca,DRUG,geodesic distance,OUTCOME,POSITIVELY IMPACTS
2703,Ayahuasca,DRUG,clustering coefficient,OUTCOME,POSITIVELY IMPACTS
2704,Ayahuasca,DRUG,local efficiency,OUTCOME,POSITIVELY IMPACTS
2706,Ayahuasca,DRUG,increase of local integration,OUTCOME,POSITIVELY IMPACTS
2707,Ayahuasca,DRUG,the entropy,OUTCOME,POSITIVELY IMPACTS
2709,the entropy,OUTCOME,increase in entropy,OUTCOME,POSITIVELY IMPACTS
2710,Ayahuasca,DRUG,increase in entropy,OUTCOME,POSITIVELY IMPACTS
2711,Ayahuasca,DRUG,increase of geodesic distance,OUTCOME,POSITIVELY IMPACTS
2712,Ayahuasca,DRUG,decrease of global efficiency,OUTCOME,POSITIVELY IMPACTS
2713,Ayahuasca,DRUG,less globally integrated,OUTCOME,POSITIVELY IMPACTS
2720,psychedelics,DRUG,elevated entropy,OUTCOME,POSITIVELY IMPACTS
2722,psychedelic state,SUBJECTIVE,elevated entropy,OUTCOME,POSITIVELY IMPACTS
2723,ordinary consciousness,SUBJECTIVE,elevated entropy,OUTCOME,POSITIVELY IMPACTS
2724,ordinary consciousness,SUBJECTIVE,reduction of freedom,OUTCOME,POSITIVELY IMPACTS
2728,psychedelics,DRUG,reduction of freedom,OUTCOME,POSITIVELY IMPACTS
2731,primary consciousness,SUBJECTIVE,elevated entropy,OUTCOME,POSITIVELY IMPACTS
2732,primary consciousness,SUBJECTIVE,reduction of freedom,OUTCOME,POSITIVELY IMPACTS
2735,ordinary consciousness,SUBJECTIVE,increase in entropy,OUTCOME,POSITIVELY IMPACTS
2738,primary consciousness,SUBJECTIVE,increase in entropy,OUTCOME,POSITIVELY IMPACTS
2741,the entropy increases,OUTCOME,increase in entropy,OUTCOME,POSITIVELY IMPACTS
2742,the entropy increases,OUTCOME,more flexible state,OUTCOME,POSITIVELY IMPACTS
2745,psilocybin,DRUG,increases of a different entropy,OUTCOME,POSITIVELY IMPACTS
2763,LSD,DRUG,increases in measures of entropy,OUTCOME,POSITIVELY IMPACTS
2765,psilocybin,DRUG,increases in measures of entropy,OUTCOME,POSITIVELY IMPACTS
2766,ketamine,DRUG,increases in measures of entropy,OUTCOME,POSITIVELY IMPACTS
2767,psychedelics,DRUG,increase the entropy in brain functions,OUTCOME,POSITIVELY IMPACTS
2769,SLN,NEURAL,the self,SUBJECTIVE,POSITIVELY IMPACTS
2770,SLN,NEURAL,self-,SUBJECTIVE,POSITIVELY IMPACTS
2774,mystical-type,SUBJECTIVE,depression,HEALTH,POSITIVELY IMPACTS
2775,mystical-type,SUBJECTIVE,anxiety,HEALTH,POSITIVELY IMPACTS
2777,psychological insight experiences,SUBJECTIVE,depression,HEALTH,POSITIVELY IMPACTS
2778,psychological insight experiences,SUBJECTIVE,anxiety,HEALTH,POSITIVELY IMPACTS
2786,mystical experiences,SUBJECTIVE,depression,HEALTH,POSITIVELY IMPACTS
2788,mystical experiences,SUBJECTIVE,anxiety,HEALTH,POSITIVELY IMPACTS
2797,psychological insight,SUBJECTIVE,anxiety,HEALTH,POSITIVELY IMPACTS
2799,insight,SUBJECTIVE,anxiety,HEALTH,POSITIVELY IMPACTS
2801,Insightful as well as mystical-type experiences,SUBJECTIVE,depression,HEALTH,POSITIVELY IMPACTS
2802,Insightful as well as mystical-type experiences,SUBJECTIVE,anxiety,HEALTH,POSITIVELY IMPACTS
2803,psychedelic,DRUG,alcohol use disorder,HEALTH,POSITIVELY IMPACTS
2804,psychedelic effects,OUTCOME,depression,HEALTH,POSITIVELY IMPACTS
2805,psychedelic effects,OUTCOME,anxiety,HEALTH,POSITIVELY IMPACTS
2806,psychological flexibility,OUTCOME,depression,HEALTH,POSITIVELY IMPACTS
2807,psychological flexibility,OUTCOME,anxiety,HEALTH,POSITIVELY IMPACTS
2808,psilocybin,DRUG,) addiction,HEALTH,POSITIVELY IMPACTS
2809,psychedelics,DRUG,biologically verified abstinence at 6 months post-treatment,OUTCOME,POSITIVELY IMPACTS
2810,psychedelics,DRUG,mindfulness/,SUBJECTIVE,POSITIVELY IMPACTS
2811,psychedelics,DRUG,acceptance,SUBJECTIVE,POSITIVELY IMPACTS
2812,psychedelics,DRUG,commitment and behavior change processes,OUTCOME,POSITIVELY IMPACTS
2816,psychedelic compounds,DRUG,"rapid, long-lasting changes in mood and behavior",OUTCOME,POSITIVELY IMPACTS
2817,DMT,DRUG,increase swimming behavior in the forced swim test,OUTCOME,POSITIVELY IMPACTS
2818,DMT,DRUG,"promoting the rapid growth of dendritic branches, spines, and synapses",OUTCOME,POSITIVELY IMPACTS
2820,psychedelics,DRUG,increase swimming behavior in the forced swim test,OUTCOME,POSITIVELY IMPACTS
2821,psychedelics,DRUG,"promoting the rapid growth of dendritic branches, spines, and synapses",OUTCOME,POSITIVELY IMPACTS
2831,DMT,DRUG,spontaneous EPSCs,NEURAL,POSITIVELY IMPACTS
2839,DMT,DRUG,very different biochemical and structural phenotypes,OUTCOME,POSITIVELY IMPACTS
2840,DMT,DRUG,promote sufficient plasticity to strengthen key circuits involved in the regulation of mood and fear,OUTCOME,POSITIVELY IMPACTS
2842,DMT,DRUG,increase glutamate release in the cortex,OUTCOME,POSITIVELY IMPACTS
2843,psychedelics,DRUG,increase glutamate release in the cortex,OUTCOME,POSITIVELY IMPACTS
2847,psychedelic compounds,DRUG,behavioral outcomes,OUTCOME,POSITIVELY IMPACTS
2848,psychedelic compounds,DRUG,gene expression of several genes related to neural plasticity,OUTCOME,POSITIVELY IMPACTS
2853,selective serotonin reuptake inhibitors,ANTIDEPRESSANT_DRUG,tolerance in humans,OUTCOME,POSITIVELY IMPACTS
2854,selective serotonin reuptake inhibitors,ANTIDEPRESSANT_DRUG,repair of damaged circuits relevant to mood and anxiety,OUTCOME,POSITIVELY IMPACTS
2855,DMT,DRUG,tolerance in humans,OUTCOME,POSITIVELY IMPACTS
2856,DMT,DRUG,repair of damaged circuits relevant to mood and anxiety,OUTCOME,POSITIVELY IMPACTS
2859,nonsubjective anesthesia,SUBJECTIVE,therapeutic effects,OUTCOME,POSITIVELY IMPACTS
2860,nonhallucinogenic psychoplastogens,DRUG,therapeutic effects,OUTCOME,POSITIVELY IMPACTS
2862,psychedelic compounds,DRUG,therapeutic effects,OUTCOME,POSITIVELY IMPACTS
2863,TBG,DRUG,therapeutic effects,OUTCOME,POSITIVELY IMPACTS
2868,mystical-like experiences,SUBJECTIVE,therapeutic effects,OUTCOME,POSITIVELY IMPACTS
2869,psychedelics,DRUG,enhanced neural plasticity,OUTCOME,POSITIVELY IMPACTS
2870,hallucinogenic effects,OUTCOME,enhanced neural plasticity,OUTCOME,POSITIVELY IMPACTS
2873,serotonergic psychedelic,DRUG,enhanced neural plasticity,OUTCOME,POSITIVELY IMPACTS
2874,serotonergic psychedelic,DRUG,postoperative mood,OUTCOME,POSITIVELY IMPACTS
2875,serotonergic psychedelic,DRUG,depressed,HEALTH,POSITIVELY IMPACTS
2876,ketamine,DRUG,postoperative mood,OUTCOME,POSITIVELY IMPACTS
2877,ketamine-induced mystical experiences,OUTCOME,postoperative mood,OUTCOME,POSITIVELY IMPACTS
2878,psychedelics,DRUG,postoperative mood,OUTCOME,POSITIVELY IMPACTS
2879,psychedelics,DRUG,depressed,HEALTH,POSITIVELY IMPACTS
2880,psychedelics,DRUG,therapeutic responses,OUTCOME,POSITIVELY IMPACTS
2882,psychedelics,DRUG,exceptionally strong placebo effect,OUTCOME,POSITIVELY IMPACTS
2888,mystical-type experiences,SUBJECTIVE,therapeutic responses,OUTCOME,POSITIVELY IMPACTS
2894,drugs,DRUG,therapeutic responses,OUTCOME,POSITIVELY IMPACTS
2895,drugs,DRUG,exceptionally strong placebo effect,OUTCOME,POSITIVELY IMPACTS
2896,drugs,DRUG,heightened neural plasticity,OUTCOME,POSITIVELY IMPACTS
2897,drugs,DRUG,treating,OUTCOME,POSITIVELY IMPACTS
2898,drugs,DRUG,depression,HEALTH,POSITIVELY IMPACTS
2899,drugs,DRUG,neuropsychiatric diseases,HEALTH,POSITIVELY IMPACTS
2900,drugs,DRUG,neurobiology,NEURAL,POSITIVELY IMPACTS
2901,drugs,DRUG,neural plasticity,OUTCOME,POSITIVELY IMPACTS
2907,rewiring pathological neural circuitry,OUTCOME,neuropsychiatric diseases,HEALTH,POSITIVELY IMPACTS
2932,psilocybin,DRUG,terminal cancer diagnoses,HEALTH,POSITIVELY IMPACTS
2935,psilocybin,DRUG,reducing symptoms of anxiety,OUTCOME,POSITIVELY IMPACTS
2937,Psychedelics,DRUG,disrupting ordinary language processes,OUTCOME,POSITIVELY IMPACTS
2938,Psychedelics,DRUG,enhance psychological flexibility,OUTCOME,POSITIVELY IMPACTS
2939,psilocybin,DRUG,psychological flexibility,OUTCOME,POSITIVELY IMPACTS
2941,psilocybin,DRUG,"habits of acceptance, connection and embodiment",OUTCOME,POSITIVELY IMPACTS
2942,psilocybin,DRUG,transformational processes,OUTCOME,POSITIVELY IMPACTS
2943,LSD,DRUG,subjective effects,OUTCOME,POSITIVELY IMPACTS
2944,LSD,DRUG,µg,DRUG,POSITIVELY IMPACTS
2946,LSD,DRUG,longer terminal elimination half-life,OUTCOME,POSITIVELY IMPACTS
2952,LSD,DRUG,increased subjective effects,OUTCOME,POSITIVELY IMPACTS
2955,LSD,DRUG,positive subjective effects,OUTCOME,POSITIVELY IMPACTS
2964,LSD,DRUG,ego dissolution,SUBJECTIVE,POSITIVELY IMPACTS
2965,LSD,DRUG,disembodiment,SUBJECTIVE,POSITIVELY IMPACTS
2968,LSD,DRUG,psychedelic doses,DRUG,POSITIVELY IMPACTS
2973,LSD,DRUG,insightfulness,OUTCOME,POSITIVELY IMPACTS
2974,LSD,DRUG,changed meaning of percepts,OUTCOME,POSITIVELY IMPACTS
2975,µg,DRUG,µg,DRUG,POSITIVELY IMPACTS
2976,µg,DRUG,insightfulness,OUTCOME,POSITIVELY IMPACTS
2977,µg,DRUG,changed meaning of percepts,OUTCOME,POSITIVELY IMPACTS
2979,LSD,DRUG,higher ratings of blissful state,OUTCOME,POSITIVELY IMPACTS
2982,LSD,DRUG,"fear, open, and trust on the VAS",OUTCOME,POSITIVELY IMPACTS
2997,LSD,DRUG,positive effects,OUTCOME,POSITIVELY IMPACTS
3000,LSD,DRUG,lower anxiety ratings,OUTCOME,POSITIVELY IMPACTS
3001,LSD,DRUG,positive mood effects,OUTCOME,POSITIVELY IMPACTS
3003,psychedelics,DRUG,µg,DRUG,POSITIVELY IMPACTS
3004,psychedelics,DRUG,lower anxiety ratings,OUTCOME,POSITIVELY IMPACTS
3005,psychedelics,DRUG,positive mood effects,OUTCOME,POSITIVELY IMPACTS
3014,LSD,DRUG,psychotropic effects,OUTCOME,POSITIVELY IMPACTS
3022,LSD,DRUG,prevented the acute effects,OUTCOME,POSITIVELY IMPACTS
3032,ketanserin,DRUG,µg,DRUG,POSITIVELY IMPACTS
3033,ketanserin,DRUG,prevented the acute effects,OUTCOME,POSITIVELY IMPACTS
3034,ketanserin,DRUG,adverse effects,OUTCOME,POSITIVELY IMPACTS
3038,µg,DRUG,adverse effects,OUTCOME,POSITIVELY IMPACTS
3040,µg,DRUG,lower depression ratings,OUTCOME,POSITIVELY IMPACTS
3053,Psychedelic microdoses,DRUG,µg,DRUG,POSITIVELY IMPACTS
3054,Psychedelic microdoses,DRUG,subjective “any drug effects,OUTCOME,POSITIVELY IMPACTS
3055,Psychedelic microdoses,DRUG,microdoses,DRUG,POSITIVELY IMPACTS
3056,Psychedelic microdoses,DRUG,prolonged effects on mood,OUTCOME,POSITIVELY IMPACTS
3057,Psychedelic microdoses,DRUG,adverse subjective effects,OUTCOME,POSITIVELY IMPACTS
3058,Psychedelic microdoses,DRUG,subjective effects,OUTCOME,POSITIVELY IMPACTS
3060,LSD,DRUG,vigilance reduction,OUTCOME,POSITIVELY IMPACTS
3077,LSD,DRUG,tartrate,DRUG,POSITIVELY IMPACTS
3121,LSD,DRUG,psychoactive in,OUTCOME,POSITIVELY IMPACTS
3137,LSD,DRUG,minidoses,DRUG,POSITIVELY IMPACTS
3141,µg,DRUG,psychoactive in,OUTCOME,POSITIVELY IMPACTS
3161,µg,DRUG,microdoses,DRUG,POSITIVELY IMPACTS
3170,LSD,DRUG,enhance blinding between the different conditions,OUTCOME,POSITIVELY IMPACTS
3171,ketanserin-LSD,DRUG,anxiety,HEALTH,POSITIVELY IMPACTS
3174,serotoninergic hallucinogens,DRUG,antidepressive,OUTCOME,POSITIVELY IMPACTS
3175,serotoninergic hallucinogens,DRUG,anxiolytic,OUTCOME,POSITIVELY IMPACTS
3176,serotoninergic hallucinogens,DRUG,antiaddictive,OUTCOME,POSITIVELY IMPACTS
3177,psilocybin,DRUG,cancer-related depression,HEALTH,POSITIVELY IMPACTS
3183,ayahuasca,DRUG,cancer-related depression,HEALTH,POSITIVELY IMPACTS
3191,psilocybin,DRUG,region-dependent alterations in neurometabolite concentrations,OUTCOME,POSITIVELY IMPACTS
3209,psilocybin,DRUG,reduced absolute CBF,OUTCOME,POSITIVELY IMPACTS
3217,psilocybin,DRUG,increases in feelings of ego dissolution,OUTCOME,POSITIVELY IMPACTS
3218,psychedelic,DRUG,increases in feelings of ego dissolution,OUTCOME,POSITIVELY IMPACTS
3219,psilocybin,DRUG,subjective experience of sense of self,SUBJECTIVE,POSITIVELY IMPACTS
3221,psilocybin,DRUG,feelings of AED,OUTCOME,POSITIVELY IMPACTS
3222,psilocybin,DRUG,ego pathology,OUTCOME,POSITIVELY IMPACTS
3223,psilocybin,DRUG,feelings of anxiety,OUTCOME,POSITIVELY IMPACTS
3226,psychedelic drugs,DRUG,feelings of AED,OUTCOME,POSITIVELY IMPACTS
3227,psychedelic drugs,DRUG,ego pathology,OUTCOME,POSITIVELY IMPACTS
3228,psychedelic drugs,DRUG,feelings of anxiety,OUTCOME,POSITIVELY IMPACTS
3229,mPFC,NEURAL,feelings of anxiety,OUTCOME,POSITIVELY IMPACTS
3230,mPFC,NEURAL,anxiety,HEALTH,POSITIVELY IMPACTS
3232,mPFC,NEURAL,feelings of positively experienced ego dissolution,OUTCOME,POSITIVELY IMPACTS
3236,psychedelic,DRUG,feelings of positively experienced ego dissolution,OUTCOME,POSITIVELY IMPACTS
3242,psilocybin,DRUG,feelings of positively experienced ego dissolution,OUTCOME,POSITIVELY IMPACTS
3243,MTL,NEURAL,feelings of depersonalization,OUTCOME,POSITIVELY IMPACTS
3244,DMN circuitry,NEURAL,feelings of positively experienced ego dissolution,OUTCOME,POSITIVELY IMPACTS
3245,DMN circuitry,NEURAL,feelings of depersonalization,OUTCOME,POSITIVELY IMPACTS
3246,psychedelic drug,DRUG,feelings of depersonalization,OUTCOME,POSITIVELY IMPACTS
3247,psychedelic drug,DRUG,feelings of (positive) ego dissolution,OUTCOME,POSITIVELY IMPACTS
3248,DMN,NEURAL,feelings of (positive) ego dissolution,OUTCOME,POSITIVELY IMPACTS
3251,sensorimotor network,NEURAL,post-traumatic stress disorders,HEALTH,POSITIVELY IMPACTS
3252,neurobiology,NEURAL,post-traumatic stress disorders,HEALTH,POSITIVELY IMPACTS
3253,psychedelic,DRUG,neurobiology,NEURAL,POSITIVELY IMPACTS
3254,psychedelic,DRUG,therapeutic relief,OUTCOME,POSITIVELY IMPACTS
3257,psychedelic,DRUG,addiction,HEALTH,POSITIVELY IMPACTS
3258,psychedelic,DRUG,post-traumatic stress disorders,HEALTH,POSITIVELY IMPACTS
3261,psychedelics,DRUG,addiction,HEALTH,POSITIVELY IMPACTS
3262,psychedelics,DRUG,post-traumatic stress disorders,HEALTH,POSITIVELY IMPACTS
3263,psychedelics,DRUG,neurobiology,NEURAL,POSITIVELY IMPACTS
3264,psychedelics,DRUG,drug-induced ego dissolution,HEALTH,POSITIVELY IMPACTS
3265,psychedelics,DRUG,therapeutic relief,OUTCOME,POSITIVELY IMPACTS
3270,psychedelics,DRUG,increases in well-being,OUTCOME,POSITIVELY IMPACTS
3274,psilocybin,DRUG,disrupted neuronal function,OUTCOME,POSITIVELY IMPACTS
3277,LSD,DRUG,increased amygdala seed-based connectivity,OUTCOME,POSITIVELY IMPACTS
3278,LSD,DRUG,decreased amygdala connectivity,OUTCOME,POSITIVELY IMPACTS
3286,LSD,DRUG,resting state connectivity,NEURAL,POSITIVELY IMPACTS
3287,LSD,DRUG,changes in amygdala responses,OUTCOME,POSITIVELY IMPACTS
3288,LSD,DRUG,prefrontal cortex,NEURAL,POSITIVELY IMPACTS
3291,LSD,DRUG,connectivity a,NEURAL,POSITIVELY IMPACTS
3292,psilocybin,DRUG,resting state connectivity,NEURAL,POSITIVELY IMPACTS
3293,psilocybin,DRUG,changes in amygdala responses,OUTCOME,POSITIVELY IMPACTS
3296,psilocybin,DRUG,prefrontal cortex,NEURAL,POSITIVELY IMPACTS
3299,psilocybin,DRUG,connectivity a,NEURAL,POSITIVELY IMPACTS
3300,psilocybin,DRUG,modulated amygdala activation,OUTCOME,POSITIVELY IMPACTS
3301,psilocybin,DRUG,decreased amygdala connectivity,OUTCOME,POSITIVELY IMPACTS
3305,drugs,DRUG,decreased amygdala connectivity,OUTCOME,POSITIVELY IMPACTS
3306,drugs,DRUG,"dampen, and thereby normalize, disrupted amygdala responses",OUTCOME,POSITIVELY IMPACTS
3311,selective serotonin reuptake inhibitors (SSRIs),ANTIDEPRESSANT_DRUG,"dampen, and thereby normalize, disrupted amygdala responses",OUTCOME,POSITIVELY IMPACTS
3313,selective serotonin reuptake inhibitors (SSRIs),ANTIDEPRESSANT_DRUG,enhancing cortico-limbic connectivity in the brain,OUTCOME,POSITIVELY IMPACTS
3316,SSRIs,ANTIDEPRESSANT_DRUG,enhancing cortico-limbic connectivity in the brain,OUTCOME,POSITIVELY IMPACTS
3317,SSRIs,ANTIDEPRESSANT_DRUG,emotion regulation,OUTCOME,POSITIVELY IMPACTS
3319,LSD,DRUG,emotional processing,OUTCOME,POSITIVELY IMPACTS
3322,LSD,DRUG,"connectivity,",NEURAL,POSITIVELY IMPACTS
3324,subjective experience,SUBJECTIVE,sense of self,SUBJECTIVE,POSITIVELY IMPACTS
3325,psilocybin,DRUG,sense of self,SUBJECTIVE,POSITIVELY IMPACTS
3327,psilocybin,DRUG,improve they affective state,OUTCOME,POSITIVELY IMPACTS
3328,psilocybin,DRUG,long lasting,OUTCOME,POSITIVELY IMPACTS
3329,psilocybin,DRUG,long lasting antidepressant effects,OUTCOME,POSITIVELY IMPACTS
3330,psilocybin,DRUG,symptoms of depression,OUTCOME,POSITIVELY IMPACTS
3331,psilocybin,DRUG,cellular proliferation,NEURAL,POSITIVELY IMPACTS
3332,psilocybin,DRUG,increased synaptic connectivity,NEURAL,POSITIVELY IMPACTS
3333,psilocybin,DRUG,anti-inflammatory effects,NEURAL,POSITIVELY IMPACTS
3338,psilocybin,DRUG,behavioral flexibility,OUTCOME,POSITIVELY IMPACTS
3342,psilocybin,DRUG,threat of drowning,SUBJECTIVE,POSITIVELY IMPACTS
3343,psilocybin,DRUG,coping strategy,OUTCOME,POSITIVELY IMPACTS
